The Texas Medical Center Library

DigitalCommons@TMC
The University of Texas MD Anderson Cancer
Center UTHealth Graduate School of
Biomedical Sciences Dissertations and Theses
(Open Access)

The University of Texas MD Anderson Cancer
Center UTHealth Graduate School of
Biomedical Sciences

5-2015

NFAT1 CONTRIBUTES TO MELANOMA TUMOR GROWTH AND
METASTASIS BY REGULATING IL-8 AND MMP-3
Einav Shoshan

Follow this and additional works at: https://digitalcommons.library.tmc.edu/utgsbs_dissertations
Part of the Medicine and Health Sciences Commons

Recommended Citation
Shoshan, Einav, "NFAT1 CONTRIBUTES TO MELANOMA TUMOR GROWTH AND METASTASIS BY
REGULATING IL-8 AND MMP-3" (2015). The University of Texas MD Anderson Cancer Center UTHealth
Graduate School of Biomedical Sciences Dissertations and Theses (Open Access). 552.
https://digitalcommons.library.tmc.edu/utgsbs_dissertations/552

This Dissertation (PhD) is brought to you for free and
open access by the The University of Texas MD Anderson
Cancer Center UTHealth Graduate School of Biomedical
Sciences at DigitalCommons@TMC. It has been
accepted for inclusion in The University of Texas MD
Anderson Cancer Center UTHealth Graduate School of
Biomedical Sciences Dissertations and Theses (Open
Access) by an authorized administrator of
DigitalCommons@TMC. For more information, please
contact digitalcommons@library.tmc.edu.

NFAT1 CONTRIBUTES TO MELANOMA TUMOR GROWTH AND METASTASIS
BY REGULATING IL-8 AND MMP-3

By
Einav Shoshan, M.S

APPROVED:

______________________________
Menashe Bar-Eli, Ph.D., Supervisory Professor

______________________________
Gary E. Gallick, Ph.D.

______________________________
Jeffrey E. Gershenwald, M.D.

______________________________
Douglas D. Boyd, PhD.

______________________________
George A. Calin, PhD.

APPROVED:

__________________________
Dean, The University of Texas
Graduate School of Biomedical Sciences at Houston

NFAT1 CONTRIBUTES TO MELANOMA TUMOR GROWTH AND METASTASIS
BY REGULATING IL-8 AND MMP-3

A
DISSERTATION

Presented to the Faculty of
The University of Texas
Health Science Center at Houston
And
The University of Texas
M.D. Anderson Cancer Center
Graduate School of Biomedical Sciences
In Partial Fulfillment
Of the Requirements
For the Degree of

DOCTOR OF PHILOSOPHY

By
Einav Shoshan, M.S.
Houston, Texas
May 2015

Dedication

I would like to dedicate this dissertation to my parents, Frida
and Moshe Oron, for their endless support.

To my brothers Haim and Gadi and my sister Merav, for their
help, interest and friendship.

To the Shoshan family for their support and faith

To my friends in Houston and in Israel, for being there at all
times, listening and helping.

To my husband Roei and my two bountiful daughters Yael and
Tamar, for their love and support over the duration of my
graduate career

iii

Acknowledgements
It is with great appreciation that I acknowledge and thank the people who have been involved
in my research projects, as well as those who have made the time during my training and
education a great experience.

I would like to express my upmost gratitude to my mentor and Ph.D. advisor, Dr. Menashe
Bar-Eli.

His patience, guidance, and encouragement allowed me to complete this

dissertation.

The amount of information I learned about melanoma, cancer, and the

metastatic process is by far the most precious knowledge I have gained throughout the my
education and it’s all thanks to Dr. Bar-Eli.

The members of my advisory, examining, and supervisory committees (Dr. Gary E. Gallick,
Dr. Jeffrey E. Gershenwald, Dr. Douglas D. Boyd, Dr. George A. Calin, Dr. Dina Lev, Dr.
Jessica Tyler and Dr. Rosemarie Schmandt) are greatly appreciated for their guidance,
support, and criticism which allowed me to become a better scientist.

The mental support, experimental help, and guidance received, along with the friendships
that were gained from the past and current lab members cannot be underestimated (Dr.
Russell R. Braeuer, Dr. Takafumi Kamiya , Dr. Aaron Mobley, Mayra Vasquez, Li Huang,
and Dr. Guermarie Valazquez-Torres, and Dr. Maya Zigler,). Their presence created a
wonderful laboratory experience that will forever be cherished. I would also like to thank
iv

friends from the Smith Research Building (Dr. Mai Tran, Dr. Rajesha Rupaimoole and all lab
members of Sood Lab) for the fun and memorable times shared.

Finally, I would like to thank all faculty members, students, and staff at the University of
Texas Health Science Center and M.D. Anderson Cancer Center, especially those of the
MDACC Cancer Biology Department.

v

NFAT1 CONTRIBUTES TO MELANOMA TUMOR GROWTH AND METASTASIS
BY REGULATING IL-8 AND MMP-3

Einav Shoshan, M.S.
Supervisory Professor: Menashe Bar-Eli, Ph.D.

Studies from our laboratory have recently demonstrated that Gal-3 regulates autotaxin
through NFAT1 and support melanoma progression. These findings prompted us to further
study the role of NFAT1 in melanoma progression and metastasis. NFAT1 is a transcription
factor that was first identified in immune cells, acting as a positive regulator of interleukin-2
by binding to its promoter during T cell activation. NFAT1 has an important role in the
innate and adaptive immune response. In this dissertation I studied the mechanisms by which
NFAT1 contributes to the acquisition of the melanoma metastatic phenotype.

To identify the role of NFAT1 in melanoma progression we stably silenced NFAT1
expression in the highly metastatic cell line, A375SM, and subjected the cells to gene
expression microarray analysis. We identified and validated two downstream targets of
NFAT1, i.e; IL-8 and MMP-3 to be downregulated following silencing NFAT1. While
silencing of NFAT1 reduced IL-8 and MMP-3 in highly metastatic cell lines, A375SM and
WM902B, overexpression of NFAT1 in the low metastatic cell line, SB2 induced the
expression of both IL-8 and MMP-3.

We further demonstrated that silencing NFAT1
vi

significantly reduced the promoter activity of IL-8 and MMP-3 and mutations of the NFAT1
binding sites at either promoter reduced the promoter activity. Rescue of NFAT1 increased
both IL-8 and MMP-3 expression back to their initial levels, indicating that they are directed
targets of NFAT1. Importantly, we demonstrated in melanoma patient specimens and cell
lines that overexpression of NFAT1 is correlated with disease progression and
staging. Moreover, our in vivo studies demonstrated that NFAT1 is a major contributor of
tumor growth and lung metastasis. The role of MMP-3 in melanoma progression has not
been previously described. Therefore, we next decided to elucidate the role of MMP-3 in
melanoma. Our in vivo studies demonstrated that MMP-3 contributes to melanoma tumor
growth and metastasis.
Collectively, our data assign a previously undescribed role for NFAT1in melanoma
progression through the regulation of IL-8 and MMP-3.
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Chapter 1: Introduction and Background

Melanoma Occurrence
Melanoma is considered to be the deadliest and most aggressive form of skin cancer.
The annual death incidence of this disease is higher than any other skin cancer [1]. The
current statistics are evidence that malignant melanoma presents a major clinical challenge
due to limited treatment options. In the United States, melanoma is documented as the fifth
and seventh most common form of cancer in men and women respectively [2]. For 2014,
there are 76,100 (43,890 in men, 32,210 in women) expected new cases of melanoma with
9,710 of those cases resulting in death [2]. Although melanoma cases represent less than 5%
of all skin cancers, it is responsible for more than 80% of deaths from skin cancer [3]. It
seems that cutaneous melanoma is relevant for all major ethnic groups and races in the USA,
however there are variations by race and ethnicity. In the USA non-hispanic white
individuals are the most likely to develop melanoma in their life period [4].

To identify

novel therapeutic molecular targets and successfully cure this disease, it is critical to
understand the molecular events that lead to melanoma metastasis.

Melanoma Development
The onset of melanoma is largely due to a cohort of cellular, tissue, and/or
environmental factors that lead to genetic and epigenetic alterations influencing the
proliferation of normal melanocytes [5].

Melanocytes are cells of the skin that are

responsible for producing the pigment melanin which in turn helps protect against the
harmful effects of ultraviolet light. Human melanocytes arise from neural crest (ectoderm)
1

cells that are only present during embryonic development and migrate in a coordinated
fashion to be effectively incorporated into every follicle of hair and every unit of the human
epidermis [6].

Over three decades ago, a study focused on the progression of tumor

development led Clark et al. to propose that melanoma develops in a stepwise manner of five
steps [7]. The first step to the model, Benign Nevus, involves the formation of a benign
nevus due to an abnormal increase in proliferation of normal melanocytes. In standard
clinical observation, these nevi will appear as either flat or slightly raised lesions on the
surface of the skin. The pigmentation of these lesions can be either completely uniform or
with a dot-like pattern [3]. In step two, Dysplastic Nevus, due to uncontrolled growth, the
development of cytologic atypia arise from these newly formed benign nevi or in an entirely
new location. Clinically, these lesions lack uniformity, such that they are typically seen with
irregularities in the borders and may contain multiple pigments [3]. Primary melanoma
develops in the third stage termed the Radial Growth Phase (RGP). In this step, cells now
have the limited ability to only penetrate the epidermis and proliferate to form tumors [3].
With progression of the tumor comes the ability of cells to fully invade the dermis to form
lesions beyond the basement membrane. This is the fourth step and it is termed the Vertical
Growth Phase (VGP). At this step, cells gain the ability to form tumors when implanted in
nude mice [3]. The fifth and final stage of the primary tumor is to form distant metastasis by
dissociating from the primary tumor, entering the lymphatic system, and transporting into
outlying organ sites to proliferate and form new tumors [3]. Among the most common sites
for melanoma metastasis are bone, lung, liver and brain. There is a second model for the
development of melanoma that suggests that melanoma does not arise from molecular
disturbances of a preexisting Dysplastic Nevus but rather as completely de novo [8]. The
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transformation of melanocytes to melanoma is promoted through the activation of different
cellular pathways that induce the genetic and epigenetic changes necessary for the
development of melanoma [9]. Although both models are plausible for occurring in humans,
the model that includes the five defined sequential steps is most widely accepted (Figure 1).

Melanoma Staging and Survival
Currently there are four distinct clinical classifications for melanoma. The factors for
prognosis are: the thickness and presence or absence of ulceration of the primary tumor, the
expression of lymph node metastasis, and the presence of distant metastatic disease [10].
Those patients who are diagnosed within the first two stages have primary tumors with no
identifiable metastasis.

Specifically, stage I melanoma is identified by the presence of

primary tumors with a thickness of less than 2mm. Furthermore, a sub-classification of stage
I, stage IA and IB, distinguishes between tumors that are less than 1mm thick with no visible
ulcerations (IA) and tumors that are also less than 1mm thick but are either ulcerated or have
greater than one mitotic cell per mm2 (IB). A tumor with thickness of up to 2mm with no
ulceration (termed T2a melanoma) is also classified as stage IB [11]. Patients with stage II
melanoma are sub-classified into either IIA or IIB depending on the tumor thickness which
ranges from 1mm to greater than 4mm, and the presence or absence of ulcerations [10]. The
stage of the disease is a critical factor in determining a patient’s prognosis, since the five year
rate of survival in patients presenting an early stage of melanoma is 90% but those in stage
IV of the disease (wide spread metastasis) only have a 10-20% chance of survival [12-16].
Crucial independent predictors for patient outcome and those that also contribute to the
variation in survival are tumor thickness, mitotic rate, and presence of ulcerations [10, 17,
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18]. Results from a 2011 study found a correlation between mitotic rate and the development
of ulcerations and concluded that at ten years, there is a 33% chance of survival for patients
with ulcerated tumors greater than 5mm as opposed to patients with ulcerations less than
5mm in diameter who have a 69% chance of survival [17, 19]. At stage III melanoma,
regional lymph node metastasis is present.

Three additional subcategories to stage III

melanoma are IIIA, IIIB, and IIIC respectively. The classification criteria depends on the
number of regional lymph nodes present, the size of the lesion within the node (micro vs,
macrometastasis), and if in transit metastasis is seen. There is a 25-35% 10 year survival rate
for patients with multiple affected lymph nodes (macrometastasis) opposed to 45-65%
survival for patients with micrometastasis, one or two lymph nodes affected [11]. Stage IV
melanoma involves patients with distant organ metastasis such as, but not limited, to the
bones, brain, and lungs. The ten year survival rate for patients in stage IV melanoma is less
than 20% [11]. Recently it was published that age is a prognostic factor in melanoma patients
and it can also be used as a predictor of sentinel node metastasis [20, 21]. These reports show
that older patients with stage I and II had lower survival rates and higher incidence of nodal
metastasis.

Current Treatments for Metastatic Melanoma
Historically, systemic therapy for metastatic melanoma was in the form of a DNA
damaging compound named decarbazine (DTIC) and it was approved by the FDA in 1975
[22]. The response rate for the alkylating agent DTIC is low, only 5-12%, with long term
response in less than 2% of patients [23], it remains as the standard treatment for many years
while new therapies were tested [24]. An oral analogue to decarbazine is temozolemide,
another alkylating agent that has a broad spectrum of anti-tumor effect and is much less toxic
4

than decarbazine [25]. Currently, temozolemide is routinely utilized in place of decarbazine
for therapeutic purposes [24]. The first nonspecific immunotherapeutic drug approved before
2011 for the treatment of malignant melanoma was a high dose of Interleukin-2 (IL-2), but it
demonstrated only a 15% response rate, and it remains nonspecific whereby treatment
requires high dosages leading to intolerability and other side effects [26]. Adjuvant therapy
is the term for a treatment that is given after surgical removal of the melanoma tumor. The
cytokine, Interferon-alpha (IFN-α) was approved for use as adjuvant therapy for patients with
early stage melanoma in order to reduce the risk for disease progression. After primary
tumors are resected, and when there is no involvement of the lymph nodes, patients can be
treated with high or low doses of IFN-α [27]. Furthermore, because of the significant dosedependent side effects linked to adjuvant therapies, careful consideration must be taken when
deciding whether or not to undergo such treatment.

Within the past years, rigorous research studies focused on understanding the
complex interaction between tumors and their microenvironment have led to the
development of some newly FDA approved anti-tumor drugs with increased immune
specificity [24]. Ipilimumab, a safer T-cell activating agent, is the first among the four most
recent drugs approved by the FDA. In 2011, ipilimumab was approved as a therapy for
advanced melanoma. Ipilimumab is a monoclonal antibody against cytotoxic T lymphocyte
associated antigen 4 (CTLA-4). CTLA-4 is responsible for inhibiting T cells to prevent
autoimmune response. Ipilimumab allowed stronger T cell activation against malignant
melanocytes, allowing prolonged immune responses to tumor antigens by preventing the
down regulation of T-cell activation [28]. A clinical study performed on cases of stage IIIC
and IV melanoma with no previous treatment found that the overall two year survival rate
5

increased by 10% when patients were treated with a combination of ipilimumab and DTIC as
compared to DTIC alone [29]. In the clinical setting, the FDA recommends the ipilimumab
regimen to consist of a concentration of 3 mg/kg per dose administered 3 weeks apart in 4
cycles [30]. However, a number of auto-immune related adverse effects including adrenal
insufficiency, rash, diarrhea/colitis, and hypothyroidism appear in patients several weeks
after being treated with ipilimumab [31].

Programmed cell death protein 1 (PD-1) is a

protein expressed on T cells and plays a role in tumor cells escaping the immune response.
When PD-1 interacts with the ligand PD-L1, it inhibits T cell proliferation and induces
apoptosis of T cells [32]. In recent years it was demonstrated that PD-1/PD-L1 plays a role in
immunosuppression of tumor cells. Using antibodies against PD-1 exhibited good results in a
phase 1 clinical trial that included melanoma [33]. Only patients expressing the PD-L1 ligand
on tumor cells were found to be suitable for the trial. Anti PD-1 and anti-PD-L1 are still
being tested [33].

The other FDA approved drugs within the last years are therapies designed to target
gene mutations of the RAS/RAF/MEK/ERK pathway. Since the most mutated protein in
cancer is BRAF, the development of vemurafenib was pivotal as a potent and specific BRAF
inhibitor [34, 35]. Currently, 40-60% of metastatic melanomas contain BRAF mutations,
where a substitution for valine at the 600th amino acid position (V600E) is the most
common, BRAFV600E mutation. To analyze vemurafenib response rate, a randomized phase 3
clinical trial that included 675 patients with stage IIIC or IV melanoma that also was both
untreated and resectable demonstrated that after treatment with an oral dosage of 960 mg
twice daily, a decrease of ~50% in tumor size was demonstrated with an improvement in
progression free survival of ~5 months and an overall 6 month survival of ~85%
6

[36]. Resistance to vemurafenib is typically seen in all patients. Either the activation of
alternative pathways or the reactivation of the mitogen-activated protein kinase creates this
resistance thereby creating a need for combination treatments that include downstream and
alternative pathway blocking agents [37, 38]. Current insights propose that a more effective
therapeutic approach involves the use of individual inhibitors to simultaneously target RAF
and MEK rather than targeting either kinase alone [39-41]. Dabrafenib was approved in May
2013 for the treatment of metastatic melanoma. This agent actively works against
BRAFV600E mutations and when compared to decarbazine, established a 3 months increase of
the progression free survival rate. Interestingly, even though dabrafenib has a reduced blood
brain barrier capability, a phase 2 study with cases involving brain metastasis with tumors
harboring the V600E mutation had an overall intracranial response rate of ~40% (previously
untreated cases) and ~30% (previously treated cases) when administering a dosage of 150 mg
dabrafenib 2 times a day [42]. Trametinib is a pharmacological MEK inhibitor that was
approved in May 2013 by the FDA, for melanoma patients with BRAFV600E mutations.
Patients treated with trametinib showed an increase of ~3 months progression free survival
compared to chemotherapy alone [43]. Two notable combination therapies are
dabrafenib/trametinib and vemurafenib/cobimetinib. In January 2014 the combination drug
dabrafenib/trametinib was FDA approved for use in treating metastatic melanoma cases with
unresectable tumors or containing BRAFV600E/V600K mutations [44]. The response rate was
~75% with response duration of ~10 months compared to treatment with dabrafenib alone
which yielded a ~55% response rate with ~ 5 month response duration [24]. Another
promising therapy is the combination of vemurafenib/with the MEK inhibitor,
cobimetinib. Although FDA approval is yet to be obtained, findings from early data suggest
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that this combination therapy significantly improves clinical outcomes in patients with
advanced BRAF V600 mutated metastatic melanoma [45]. The rate of response is increased in
more than 20% in the combination group compared to the control group. Furthermore, an
increase of ~10% in overall survival rate is observed in the combination group [45].

Genetic Alterations during Melanoma Progression
A wide array of both genetic and epigenetic events takes place throughout the
progression of melanoma which leads to the initial formation of cutaneous melanoma and
eventually metastasis. There are several genes whose genetic changes play a fundamental
role in transitioning the initial stage of melanoma (benign nevi) to premalignant lesions.
Some of these important genes includes: NRAS, cyclin D1, PTEN, BRAF, and CDKN2A.
BRAF is an oncogene that when mutated has the potential to cause normal cells to
become cancerous.

As a member of the RAF family, BRAF acts on the map kinase

(MAPK), RAS/RAF/MEK/ERK signaling pathway [46]. An amino acid substitution at
position 600 from a valine (V) to a glutamic acid (E) in BRAF results in the V600E mutation.
The V600E mutation in BRAF along with NRAS, the upstream molecule that activates
BRAF, are indicators of the critical role that the MAPK pathway plays in melanoma
progression. While the V600E mutation is seen in approximately 40-60% of melanoma
cases, only 20-30% of the upstream NRAS mutations are present [47-50]. These two
mutations are mutually exclusive in melanoma. Contradictive to the records that suggest
BRAFV600E is essential for melanoma progression is a study that has shown that although
80% of melanocytic nevi contain BRAF mutations, not all progress into primary melanomas
[51] and that the introduction of BRAFV600E in melanocytes can induce cell senescence and
apoptosis [52]. An explanation for this event comes from the presence of other molecules,
8

such as the tumor suppressor gene cyclin dependent kinase inhibitor 2A (CDKN2A) which
inhibits BRAFV600E and therefore prevents BRAF from releasing cells from senescence and
inducing cell growth.

CDKN2A is important in melanoma progression since (through

alternative mRNA splicing) this gene encodes p16Ink4A, a known inhibitor of cyclin D/CDK4
complex, and p14ARF, an inhibitor of MDM2, which regulates p53 [46, 53, 54].

The

proliferating effects of BRAFV600E are restricted since an increase of p16Ink4A expression is
observed in melanocytic nevi in comparison to normal dermis [55]. Primary melanomas
have a 7% incidence of mutations in the p16Ink4A gene while it is present in 14% of metastatic
lesions [56]. Mutation in the CDKN2A gene is often linked to patients with melanoma in
their family history or UV exposure/damage. There are other genetic events that could adopt
NRAS and BRAF mutations, which influence a greater chance of developing the disease [57,
58].
The loss of PTEN is also an important determinant in melanoma development. The
action of PTEN is that of a phosphatase which removes phosphates from phosphatidylinositol
phosphate (PIP3) which then behaves like an intracellular signal catalyzed by growth factors
or other stimuli [3, 59].

PIP3 recruits the protein phosphoinositide-dependent kinase 1

(PDK1). Then, PDK1 phosphorylates AKT, which acts as a survival factor [60].

The

phosphatase PTEN dephosphorylates PIP3 (PtdIns (3,4,5)) on the 3 position, generating PIP2
(PtdIns (4,5)) and causes inactivation of the AKT signaling cascade [59]. Early studies
indicated that the deletion on chromosome 10q occurs in melanoma in 30-50% of melanomas
[61, 62], and later this deletion was connected with the location of the tumor suppressor
PTEN which is located within the long arm of chromosome 10, specifically chromosome
band 10q23.3 [63, 64]. It was discovered that 60% of melanoma cell lines carry hemizygous
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deletions of chromosome 10q [64] and 10% can be observed in primary melanomas [65, 66].
Immunohistochemistry studies revealed that almost all melanomas without PTEN expression
showed no deletion or mutation suggesting that the loss of expression can also be a result of
transcriptional repression or epigenetic regulation [67]. PTEN loss-mediated AKT activation
promotes cell survival and proliferation in melanoma [68].

In the step involving the

transition from dysplastic nevus to primary melanoma, the phosphorylation of AKT is
increased and multiple processes are affected [68]. One example is the increased interactions
between AKT and N-cadherin which leads to inactivation of BAD the pro-apoptotic protein.
This interaction promotes melanoma cell survival [69]. AKT activation in melanoma is also
associated with the upregulation of NFkB. AKT phosphorylates the protein IKKβ inducing
its activity and then IKKb phosphorylates IKβ which is an inhibitor of NFκB. In that way,
removing IKβ inhibition allows for NF-kB to be actively transcript. NFκB is responsible for
the transcription of angiogenic and pro-tumorogenic genes as VEGF, Cox-2, Bcl-2, MMPs
and IL-8 among others [70, 71].
In the last two decades our lab is investigating the molecular and cellular changes that
occur during the shift from RGP to VGP in melanoma progression. The transcription factor
activator protein 2 alpha (AP2α) is lost during this transition [72-74]. This is a specific
characteristic of the melanoma phenotype since less metastatic melanoma cells have higher
AP2α expression when compared to highly metastatic cell lines [75]. AP2α is 52 kD and is
regulated by cyclic AMP (c-AMP) and retinoic acid (Vitamin A) [76-78]. AP2α expression is
inversely correlated with genes like the protease activated G-protein coupled receptor (PAR1) and the membrane adhesion molecule MCAM/MUC18 that are known to be pro
tumorogenic [75, 79]. As a mode of action, AP2α will bind to the promoters of both
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MCAM/MUC18 and PAR-1 to suppress their transcriptional activity [72-75, 79]. Loss of
expression of nuclear AP2α is connected to melanoma progression through an observable
increase in MCAM/MUC18 and PAR-1. MCAM/MUC18 is a cell adhesion molecule, and
silencing it leads to a reduction in melanoma tumor growth and metastasis [80].
PAR-1 is another important molecule that plays a role in melanoma progression. It is
an inflammatory molecule known to be upregulated during the RGP to VGP transition.
PAR-1 promotes normal platelet aggregation through its cleavage in the extracellular domain
by thrombin. In melanoma, PAR-1 enhances vascular endothelial growth factor (VEGF) and
matrix metalloproteinase-2 (MMP2) expression in the microenvironment, thus supporting
tumor growth and metastasis. PAR-1 increases the expression of Connexin-43, another pro
tumorogenic gene and suppresses maspin, a known tumor suppressor gene [81-83].
Silencing of PAR-1 has shown reduction in melanoma growth and metastasis via Connexin43 [82].
c-AMP response element binding protein (CREB) is another transcription factor that
significantly overexpressed during the transition from RGP to VGP. Previous reports from
our laboratory have shown that CREB serves many important functions during this transition
[84, 85], including acting as a survival factor and increasing cell invasion by regulating
MMP2, IL8, BCL2, MCAM/MUC18, and the tumor suppressor CYR61 [86-89].
Furthermore, CREB regulates other important transcription factors involved in melanoma
progression such as, MITF and AP2α [90, 91]. To further evaluate CREB’s role during
melanoma progression, recently we performed gene expression profiling in metastatic
melanoma cells following CREB silencing and identified an important and previously
unknown target for CREB, the RNA-editing enzyme adenosine deaminase acting on RNA 1
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(ADAR1).

The activation of CREB plays an important role in regulating genes that are

important for inflammation, invasion, and survival [87, 92, 93]. CREB is activated through
phosphorylation at Ser133 and binding to the co-activators CBP and p300 [94, 95]. During
melanoma progression, the activation of CREB can both induce the expression of various
pro-tumerogenic genes including MCAM/MUC18 and MMP2 [87] as well as inhibit the
expression of other genes, like CYR61. CYR61 has been shown to be a regulator of cell
proliferation, survival, migration, and extracellular matrix formation [96]. Upon silencing
CREB, CYR61 expression is increased and motility and invasion reduced in vitro. Silencing
CREB reduced tumor growth and metastasis in melanoma in vivo [89]. Melanoma cells
become susceptible to apoptosis when a dominant negative form of CREB is overexpressed
[86]. Silencing CREB increases p21waf1, a cell cycle inhibitor, while an increase in CREB
activity directly suppresses AP2α expression during melanoma progression. Since AP2α is a
positive regulator of p21waf1, CREB has a significant effect on melanoma cells through its
regulation of other transcription factors that in turn regulate different genes [91]. Past and
latest findings emphasize the importance of CREB in melanoma growth and metastasis as the
“master switch” in melanoma progression.
Activating transcription factor -2 (ATF-2) which belongs to the CREB family, also
has been shown to have a role in melanoma progression [97, 98]. When ATF-2 is activated it
promotes melanoma progression and cell growth by inducing such genes as c-Jun and TGFβ.
Silencing ATF-2 reduced tumor growth and metastatic potential of melanoma cells [98, 99].
Many other important transcription factors are being deregulated during melanoma
progression. SNAIL and SLUG transcription factors are known to inhibit transcription of Ecadherin [100]. Silencing SLUG increased melanoma susceptibility to chemotherapeutics as
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cisplastim [101] . The TWIST transcription factor is known to be a metastasis regulator in
epithelial cancers responsible for epithelial-to-mesenchymal transitions (EMT). However, in
melanoma its role is unclear due to the ambiguous role of EMT in melanoma invasiveness
and metastasis [102]. Inspite all these new modalities, further research is needed to
understand the biology since BRAF resistance and the fact that only 30-40% response to
immunecheckpoint therapies. All these genetic alterations mentioned and many other
molecular classifications in melanoma progression are very important for planning new
targeted therapies. Another molecule contributing to melanoma growth and metastasis is
Galactin-3 (Gal-3). Our studies identified Gal-3 as the major regulator of autotaxin and
NFAT1. This thesis will concentrate on the transcription factor, NFAT1 and further
investigate the contribution of NFAT1 to the metastatic melanoma phenotype.
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Figure 1: Molecular and Genetic Changes During Melanoma Progression
The progression of melanoma is a stepwise process. From benign nevus to dysplastic nevus genetic
mutations occur within the BRAF or NRAS genes. The loss of PTEN or p16 INK4A/ARF expression are
early events in a subset of melanomas. The tumor then grows radially throughout the epidermis
termed the radial growth phase. The acquisition of multiple factors such as CREB and NFB
activation as well as enhanced expression of MCAM/MUC18, PAR1, Il-8, MMP-2 and galectin-3
induce the degradation of the basement membrane and invasion of melanoma cells termed the vertical
growth phase (VGP). Finally, a few select melanoma cells intravasate, circulate, and survive in
distant organ sites where metastasis forms. This figure reproduced with permission from (Miller AJ
and Mihm MC Jr., N Engl J Med 2006 [3]), Copyright Massachusetts Medical Society, and
Melnikova et al. Cancer Biol Ther 2008 [87].
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Nuclear Factor of Activated T cell – NFAT Transcription Factor
Nuclear Factor of Activated T cell (NFAT) proteins were first identified in T cells as
activators of the transcription of interleukin 2 [103, 104], which serve as a key regulator of T
cell immune response. NFAT family members are transcription factors that play an important
role in inducing the transcription of central genes during the immune response. All family
members have a highly conserved REL-homology domain (RHD), which is a DNA binding
domain.

They are also involved in the control of T cell development and T cell

differentiation [105]. Many years after the discovery of the NFAT gene family, they were
found to play many roles in other biological systems besides the immune response. Despite
their name, proteins from the NFAT family are expressed also on other cells and not only on
T cells.
Calcium flux, calcineurin and NFAT kinases are the regulators of NFAT family. Calcium
that is released from intracellular stores increases the levels of intracellular calcium. Calcium
binds to calmodulin which then activates the calcineurin phosphatase. In order to be active,
NFAT proteins are regulated by calcineurin, a phosphatase that dephosphorylates NFAT
proteins to uncover their nuclear localization site (NLS), thus triggering their mobilization
from the cytoplasm to the nucleus. In the nucleus, NFAT proteins cooperate with other
factors to regulate gene expression for various biological functions [105]. The phosphatase
calcineurin responds to a continued rise (not transient) of calcium in the cytoplasm, therefore
NFAT is dephosphorylated and imported into the nucleus for the duration of the transcription
[106]. In order to dephosphorylate NFAT, calcineurin needs to stably dock on NFAT, usually
on a region located on the protein N-terminal. Furthermore, the weak DNA binding of NFAT
requires that NFAT partner with other factors to perform transcription regulation. Such
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partners can be MEF to control muscle development, GATA in heart development, FOXP3
to regulate immune tolerance and AP-1 to activate T cell response [107, 108].
The NFAT family of proteins contains five family members, NFAT1-NFAT5, that
are all evolutionarily related to the Rel family. There are four typical members in the NFAT
family (NFAT1-4) that indeed are regulated by calcinurin, in difference to these; NFAT5
does not require calcineurin or a nuclear partner for its activity. The NFAT protein family
(NFAT1-4) has few functional modules sites on the protein: phosphorylation sites, nuclear
localization site, DNA binding site, and transactivation sites (Figure 2). The N-terminal
region includes regulatory domains like, casein kinase 1 (CK1), calcineurin (Cn) docking
sites, and transactivation domain (TAD). The C-terminus includes the nuclear localization
site (NLS), DNA-binding Rel homology domain (RHD) and an additional calcineurin
docking site. In the middle of the protein there are several serine rich domains (SP1-3) that
provide phosphorylation sites for kinases targeting NFAT. Furthermore, the NFAT protein
contains two signal sequences that regulate its subcellular localization: the nuclear
localization signal sequences (NLS1 and NLS2) and the nuclear export signal (NES) (Figure
2). When NFAT proteins are phosphorylated on their serine residues, they are localized in
the cytoplasm [108]. The activation of receptors on the cell surface for example: receptor
tyrosine kinases (RTKs), T cell receptor (TCR), receptors, and G protein coupled receptors
(GPCRs), lead to a signaling cascade that starts causing calcium influx into the cytoplasm.
When this influx is sustained, it causes the activation of calcineurin, which then
dephosphorylates the cytoplasmic NFAT proteins. Dephosphorylation of NFAT by
calcineurin exposes the nuclear localization site (NLS), causing the protein to transfer into
the nucleus [109]. Calcineurin can be inhibited by the immunosuppressant cyclosporine A
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(CsA) and tacrolimus (FK506), which form binding protein complexes which bind and
competitively inhibit calcineurin phosphatase activity [110]. To neutralize NFAT activation,
it needs to be rephosphorilated and mobilized outside the nucleus. Several kinases act to
phosphorylate NFAT proteins, for example: protein kinase A (PKA), casein kinase 1 (CK1)
and more. In the immune system the NFAT family of proteins is well established and their
role in activating T cells is clear. There is an established clinical knowledge of NFAT being
active in the regulation of T cells and in organ rejection after transplantation. Inhibitors like
CsA and FK506 help in preventing this rejection. However the functions of the NFAT family
of proteins in other aspects of human diseases and cancer are largely unknown.
In recent years there is more and more evidence that the NFAT family members are
also involved in cancer development and metastasis. Phenotypes such as increase cell
growth, enhanced proliferation, stimulates angiogenesis and increased resistance were
reported in the literature about the NFAT family [111]. In our research we have been
concentrating on one NFAT family member the NFAT1. Here in I will test the hypothesis
that NFAT1 is not solely involved in T cell activation but could also regulate the melanoma
metastatic phenotype.
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Figure 2: Primary Structure of NFAT
Schematic structure of NFAT. The region of highest homology within NFAT proteins is the DNAbinding Domain, Rel homology domain (RHD), which shows similarity to the Rel homology region
of Rel-family transcription factors. A second region of homology is the NFAT homology region
(NHR), which contains all regulatory domains. The N-terminal region includes regulatory domains
like, casein kinase 1 (CK1), calcineurin (Cn) docking sites, and transactivation domain (TAD). The
C-terminus includes the nuclear localization site (NLS), DNA-binding Rel homology domain (RHD)
and an additional calcineurin docking site. In the middle of the protein there are several serine rich
domains (SP1-3) that provide phosphorylation sites for kinases targeting NFAT. Furthermore, the
NFAT protein contains two signal sequences that regulate its subcellular localization: the nuclear
localization signal sequences (NLS1 and NLS2) and the nuclear export signal (NES).

18

Nuclear Factor of Activated T Cell 1 – NFAT1
NFAT1, also known as NFATc2, is the first member of the NFAT family that was
discovered on T cells. NFAT1 is a transcription factor bound to the antigen receptor response
element on the interleukin-2 (IL-2) promoter. NFAT1 family member is expressed on T
lymphocytes but also on many other cells outside the immune system. In equilibrium,
NFAT1 is

greatly phosphorylated and its activation can be reached through

dephosphorylation by calcinurin phosphatase [105]. Similar to the other family members,
NFAT1 activation can be blocked using calcineurin inhibitors like tacrolimus (FK506) or
cyclosporine (CsA) [110]. The dephosphorylation of NFAT1 helps the protein to be relocated
into the nucleus and to be active as a transcription factor, as previously described. In recent
years there is more and more evidence that NFAT1 is associated with cancer.
NFAT1 in Cancer
NFAT1 was published to be associated with cancer; it was showen to be associated
with a wide range of tumor progression events such as: invasion, migration, tumor cell
survival, and apoptosis. In breast cancer, high expression of NFAT1 was found in patients’
specimens with primary tumors or lymph node metastasis, when compared to healthy tissue
[112]. It was also found that there is a negative cross talk between NFAT1 and Stat5
signaling cascades [112]. These results highlight the effect of NFAT1 on breast tumor
formation and metastasis. Primarily in breast cancer, it was demonstrated that NFAT1
enhances cell invasion and cell motility by regulating a variety of downstream genes [113].
One of the mechanisms by which NFAT1 to promote cell invasion in breast cancer was
found to be through the induction of Cyclooxygenase-2 (COX-2), which is responsible for
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the production of prostaglandins [114]. In 111 clinical samples of glioblastoma, NFAT1 was
overexpressed compared with lower grade gliomas. NFAT-1 expression in glioblastoma cell
lines was correlated with higher invasion and with the expression of genes which enhance
invasion such as: MMP-7, MMP-9 and COX-2 [115]. In the melanoma literature there are
few works done on NFAT1. NFAT1 deficient mice (NFAT1-/-) presented less experimental
lung metastasis growth after melanoma cell injections when compared to the WT mice [116].
The absence of NFAT1 expression in the microenvironment causes a significant difference in
the ability of the B16F10 melanoma cell line to progress [116]. Further research presents
NFAT1 as a potential therapeutic target in melanoma, since NFAT1 was found to inhibit
melanoma cell apoptosis and promoting proliferation [117]. NFAT1 was found to be an
activating transcription factor for the MDM2 oncogene and as a response to DNA damage
signals, NFAT1-MDM2 pathway is activated to inhibit p-53 function [118]. NFAT1 was
demonstrated to support tumor-induced anergy of CD4+ T cells [119] as well as regulate a
set of genes that are responsible for helper T-cell (CD8+) anergy [120]. A recent paper
demonstrated that NFAT1 increased CTLA-4 promoter activity at CD4+ T cells compared to
CD8+ T cells. This preferential expression of CTLA-4 on CD4, which is mediated by
NFAT1, can be important for the anti CTLA-4 therapy [121]. All these data clearly indicate
that NFAT1 is a regulator of multiple genes during cancer progression. Yet in melanoma the
majority of the downstream genes are still not identified and the effect of NFAT1 on
melanoma metastatic phenotype still needs to be elucidated. Our laboratory has previously
demonstrated that Gal-3 contributes to melanoma growth and metastasis via the regulation of
autotaxin and NFAT1 [122]. In this present thesis I will expand on these results and identify
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other targets genes, besides autotaxin, that are regulated by NFAT1 and contributing to
melanoma growth and metastasis (see specific aims).

Figure 3: Calcium Signaling and Activation of NFAT1
Activation of the T-cell receptor (TCR) triggers the activation of receptor-associated tyrosine kinases
that lead to the activation of phospholipase C- (PLC- ). Activated PLC- causes the hydrolysis of
phosphatidylinositol-4,5-bisphosphate (PIP2), which generates inositol-1,4,5-trisphosphate (IP3) and
diacylglycerol (DAG). IP3 binds to its receptor and induces an increase in intracellular calcium levels
that is caused by the depletion of intracellular stores. This increase triggers the opening of calciumrelease-activated calcium channels (CRAC) in the plasma membrane, which leads to a sustained
increase in intracellular calcium levels. Calcium binds calmodulin(CM) and activates calcineurin
(Cn). Activated calcineurin dephosphorylates nuclear factor of activated T cells (NFAT1) proteins,
which exposes their nuclear-localization signal (NLS) and induces their nuclear translocation. After it
has entered the nucleus, NFAT1 interacts with activator protein 1 (AP1) and other transcriptional
partners to promote gene transcription. The activation of these partners during T-cell stimulation
might be elicited by signals that are transmitted through different signalling pathways. The activity of
NFAT1 is also regulated by kinases, such as casein kinase 1 (CK1) and glycogen-synthase kinase 3
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(GSK3), which help to maintain NFAT1 in a phosphorylated state in the cytosol (maintenance
kinases) or induce the rephosphorylation of nuclear NFAT1 to expose a nuclear-export signal (NES)
and translocate NFAT1 back to the cytosol (export kinases).

Specific Aims

NFAT1 was historically identified as inducible transcription factor in T cells [103]. In
melanoma it was shown that NFAT1 expression in the microenvironment increases the
invasive and metastatic phenotype of B16F10 murine melanoma cells [116]. We have
previously shown in our lab that Galactin-3 is regulating autotaxin through NFAT1 in
melanoma [122]. It is possible that in melanoma there are additional novel genes that could
be regulated by NFAT1 to support melanoma growth and metastasis. Therefore we
hypothesized that in addition to its role in the immune system, and to autotaxin
regulation in melanoma, NFAT1 regulates the expression of additional downstream
targets that contribute to the metastatic melanoma phenotype.

To test this hypothesis we developed the following specific aims:

Specific Aim 1: To Determine the Status and Contribution of NFAT1 to Melanoma
Progression
1.1 Examine the Status of NFAT1 in Melanoma Progression
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1.2 Study the In Vitro and In Vivo Effects of Silencing NFAT1 in Metastatic Melanoma
Cell Lines and the Effects of Overexpression NFAT1 in Low Metastatic Cell Lines

Specific Aim 2: To Identify Novel NFAT1 Downstream Target Genes that Contribute to
the Metastatic Melanoma Phenotype
2.1 Study NFAT1 as a Potential Regulator of IL-8 Expression in Melanoma Cells
2.2 Study NFAT1 as a Potential Regulator of MMP-3 Expression in Melanoma Cells
2.3 Determine the Contribution of MMP-3 to Melanoma Growth and Metastasis
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CHAPTER 2: Materials and Methods

Cell lines and Cell Culture
Human A375SM cells were collected from nude mice that were i.v injected A375P (parental)
cells, pooled lung metastasis and grown in culture as described previously [123]. The human
SB2 melanoma cell line was isolated from a primary cutaneous lesion and is non-metastatic
and poorly tumorigenic in mice [124]. WM902B cell line was isolated from skin malignant
melanoma in the vertical growth phase (VGF). All cell lines were cultured in Eagles
minimum essential media (MEM) supplemented with 10% fetal bovine serum (FBS), and 1%
of HEPES buffer, penicillin-streptomycin, sodium pyruvate and nonessential amino acids,
and kept at 37°C in a 5% CO2 incubator. The human embryonic kidney cells (293FT) were
used for lentiviral shRNA and overexpression vectors were maintained in DMEM
supplemented with 10% FBS. Sixteen hours before each in vivo injection experiment, cells
were replenished with fresh 10% FBS MEM. Cell lines in exponential growth phase were
harvested by 2-5 minutes exposure to 0.25% trypsin-0.02% EDTA solution. The cells
removed from flasks were pipetted to generate a single-cell suspension. The cells were
resuspended in PBS to the desired cell concentration just before the injecions. Cell viability
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was determined by trypan blue exclusion and only single-cell suspensions with more than
95% viability were used for in vivo injections.

Lentiviral shRNA
NFAT1 targeting shRNA 5’- CTGATGAGCGGATCCTTAA -3’ or MMP-3 targeting
shRNA 5’-TCTGAACAAGGTTCATGCT-3’ and Non Targeting (NT) shRNA 5’TTCTCCGAACGTGTCACGT-3’ were designed with a hairpin and inserted into a pSIH-HIcopGFP lentiviral vector. The lentivirus was then produced by transfecting 293FT cells with
the pSIH vector containing either the NFAT1/MMP-3 or NT shRNA sequence, the
packaging plasmid (MD2G), and the envelop plasmid (PAX2) to produce a viable virus. The
NT shRNA has no homology to any known human genes. The supernatant was collected
containing a mature virus and was concentrated 10 times. A375SM and WM902B cells were
plated at 70% confluence on a six well plate and were transduced with 800ul MEM / 200ul of
supernatant containing the virus and were incubated overnight. The cells were then grown in
culture and the top 50% GFP expressing cells were cell sorted by FACS.

Nontargetable NFAT1 Expression Vector, Empty Vector (EV)
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The NFAT1 gene (Isoform D) was amplified from A375SM cDNA with the following
primers;

Forward

5’-

ATAAGAATGCGGCCGCGCCACCATGCAGAGAGAGGCTGCGTT
CAG-3’ and Reverse 5’- GCTCTAGATAATATGTTTTGTATCCAGCTAAG-3’, cut with
NotI and XbaI restriction enzymes, and inserted into the pCDNA3.1(+) vector. The NFAT1
shRNA targeting site was mutated to CAGACGAACGCATACTAAA (the underlined
nucleotide are the entitled mutated sites) with the following primers; nfat1-Forward 5’CTTCAGATCTT CATTGGGACAGCAGACGAACGCATACTAAAGCCGCA
CGCCTTCTACCAGG-3’ and Reverse- 5’-CCTGGTAGAAGGCGTGCGGCTTTAGTAT
GCGTTCGTCTGCTGTCCCAATGAAGATCTGAAG-3’. This construct was used as a
control for both NFAT1 rescue in highly metastatic A375SM and WM902B cells and
NFAT1 overexpression in the low metastatic SB2 cells throughout the work.

NFAT1 overexpression Lentiviral Vector
NFAT1 gene (Isoform D) was cloned fromA375 cDNA into pCDNA3.1(+), using the
following

primers

NFAT1XbaIF-5’-GCTCTAGAGCCACCATGCAGAGAand

GAGGCTGCGTTCAG-3’

NFAT1NotIR-5’-

ATAAGAATGCGGCCGCTCATAATATGTTTTGTATCCAG-3’. NFAT1 gene was cut
with the designated restriction enzymes, inserted into a pCDH-CMV-MCS-EF1-puro vector
and packaged with MD2G and PAX2 plasmids in a lentiviral virus as previously described.
SB2 cell line was plated at 70% confluence on a six well plate and then transduced with
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800ul MEM / 200ul supernatant containing virus overnight and were selected with MEM
containing 1ug/ml puromycin.

NFAT1 Rescue Lentiviral Vector
NFAT1 rescue gene was generated on NFAT1-pCDNA3.1(+), using the following primers
NFAT1-res-F- 5’-CTTCAGATCTTCATTGGGACAGCAGACGAACGCATACTA
AAGCCGCACGCCTTCTACCAGG-3’ and NFAT1-res-R- 5’-CCTGGTAGAAGGCGTGC
GGCTTTAGTATGCGTTCGTCTGCTGTCCCAATGAAGATCTGAAG-3’. NFAT1 rescue
gene was cut with the designated restriction enzymes, inserted into a pCDH-CMV-MCSEF1-puro vector and packaged with MD2G and PAX2 plasmids in a lentiviral virus as
previously described. A375SM and WM902B cell lines which NFAT1 was silenced using
NFAT1 shRNA lentiviral vector were plated at 70% confluence on a six well plate and then
transduced with 800ul MEM / 200ul supernatant containing virus overnight and were
selected with MEM containing 1ug/ml puromycin.

MMP-3 Overexpression Lentiviral Vector and Nontargetable MMP-3 vector -EV
MMP-3 gene overexpression plasmid was purchased from shRNA and ORFeome core
facility at MD Anderson. The gene was inserted into a PLOC vector which has RFP and
Blasticidin as markers and packaged in a lentiviral virus as previously described.
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Nontargetable MMP-3 expression vector (EV) was purchased from shRNA and ORFeome
core facility at MD Anderson as well. SB2 cell line was plated at 70% confluence on a six
well plate and then transduced with 800ul MEM / 200ul supernatant containing virus
overnight and were selected with MEM containing 1ug/ml puromycin.

Fluorescence activated cell sorter and flow cytometry (FACS)
A375SM, WM902B and SB2 cells which were transduced with lentiviral constructs were
detached from the flask using Tripsin EDTA 0.05%. Cells were centrifuged at 1400 rpm and
the supernatant was removed. Cells were than resuspended in 500ul of PBS and were obtain
into FACS.

Protein extraction
Total protein extracts were acquired from 70%-80% confluent cell culture on a six well plate
or 10 cm dish. Cells were washed twice with cold PBS. After complete drain of PBS cells
were incubated 10 min on ice with 200ul of RIPA “B” lysis buffer (1% Triton x-100, 150mM
NaCl, 5mM EDTA, 20mM Sodium Phosphate, pH-7.4) supplemented with 1% protease
inhibitor cocktail (Roche). Cells were scraped from the plate using a scraper and lysates were
transferred into a 1.5ml clean tube. After 30sec of vortexing, lysets were centrifuged at
14,000 rpm at 4oC for 15 min and supernatant was collected. Protein concentration was
measured using Bradford assay (Bio-Rad).
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Western Blot Analysis
To detect NFAT1, 20ug of whole cell protein lysate was loaded onto 8% SDS-PAGE and
transferred into 0.45um Polyvinylidene Difluoride (PVDF) membranes (Millipore).

To

detect MMP-3 protein expression, which is a secreted protein therefore expressed best in the
medium, one million cells were plated in a 10cm dish and were incubated in serum starvation
conditions with 5ml of serum free MEM for 48hrs. The supernatant from cell culture was
concentrated to 100ul. A total of 10ug of protein from the supernatant was loaded onto 10%
SDS-PAGE. The membranes were blocked with 5% milk for 1 hour. Blots were incubated,
usually over-night at 4oC, with primary antibodies with the right dilution. Rabbit polyclonal
anti-NFAT1 1:1000 (Santa Cruz Biotechnology); Rabbit polyclonal anti-MMP-3 1:1000
(Abcam), Rabbit polyclonal anti beta-Actin 1:2000 (Santa Cruz). Proteins were detected by
ECL detection system (GE Healthcare). To confirm equal loading of the supernatant, the
membrane was coomassie blue stained and destained with 40% methanol, 50% water, and
10% acetic acid until protein bands were visible.

Matrigel Invasion Assay
Matrigel invasion assays were performed using Biocoat Matrigel invasion chambers (BD
Biosciences). Briefly, 1x105 cells diluted in 500 l of serum-free MEM and were placed on
top of the upper chamber of the Matrigel plate in triplicates. The lower chamber contained
MEM supplemented with 20% FBS. Matrigel plates were incubated for 40 h at 37 °C.
Hema3 stain set was used to stain the cells which migrated to the lower surface of the
Matrigel filter (Fisher Scientific). Filters were glued on a microscope slide. Pictures from
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different fields where taken under light microscope and the stained cells were counted and
statistically analyzed.

In vitro proliferation assay
One thousand of the cells that were used in this experiment, were plated in each well of a
ninety six well plates that were used in this experiment (12 repetitions for each sample). The
cells that were plated were the highly metastatic melanoma cell lines A375SM and WM902B
NT and NFAT1 shRNA and the low metastatic cells SB2 EV and NFAT1 overexpression.
The cells were cultured for 5 days in 10% FBS normal growth MEM medium. Cell growth
was analyzed by the colorimetric MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide) assay that determines relative number of cells based on the conversion of MTT to
formazan (has a purple color) in viable cells. Each day after plating the cells, MTT (Sigma)
was added to each well at a 1mg/ml concentration in PBS, 20ul for each well. After addition
of the MTT, a 2 hr incubation period was applied at 37°C. Medium and MTT were removed
from the wells and were replaced by 100ul of diametyl sulfoxide (DMSO, Sigma). After 1 hr
of incubation at room temp with DMSO the plate was read and quantified by measuring
absorbance at 570nm using Epoch BioTek plate reader. This procedure was repeated daily
over 5 years in order to compare if there are differences between the proliferation rates of cell
lines that were NFAT1 manipulated using lentivirous stable transduction.

Reverse transcription-PCR
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Regular PCR: RNA isolation was performed with the RNAqueous kit (Ambion). One
microgram of total RNA was reverse transcribed (RT) using the High Capacity cDNA
Reverse Transcription Kit (Applied Biosystems).

One microgram Real time PCR was

performed with the Taqman Gene Expression Assay and standardized to GAPDH (Applied
Biosystems). NFAT1, IL-8 and MMP-3 Taqman Gene Expression Assays were acquired
from Applied Biosystems and qRT-PCR was performed on A375SM WM902B and SB2
melanoma cell lines. Each probe was standardized to one with control sample.

Quantitative Real time PCR (qRT-PCR)
RNA (20 ng/μl) from the A375SM, WM902B and SB2 cell lines was harvested using a
mirVana kit (Ambion) according to the manufacturer's instructions. The RNA was then
transcribed into cDNA using TaqMan reverse transcriptase reagents for general cDNA. The
primers for NFAT1, IL-8 and MMP-3 and fluorescence probes were obtained from Applied
Biosystems. Reaction components for reverse transcription-PCR and amplifications were
described previously [81]. Amplifications were run in triplicates, and averages were obtained
after normalization with 18s (Applied Biosystems). Data was expressed in -fold change.

Chromatin Immunoprecipitation Assay (ChIP)
ChIP Assay was performed using ChIP-IT Express Kit (Active Motif) according to the
manufacturer’s protocol. 1×107 melanoma cells were plated in 15 cm culture dishes. The next
day cells were fixed with 37% Formaldehyde containing medium. The cells were then
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scraped from plates, and cell suspensions centrifuged for 10 minutes at 2500 rpm at 4 °C.
Supernatant was discarded. The cells at the bottom of the tube were then lysed and incubated
on ice for 30 minutes. Next, chromatin enzymatic shearing was performed to cut the DNA to
fragments sized between 200-1000-bp. Fixed protein DNA complexes were then pulled down
using magnetic beads with anti-NFAT1 antibody (Santa Cruz) followed by separation from
the magnetic beads and Protein-DNA reverse cross-linking at 65°C for 2.5 hours. Next, the
proteins were digested for one hour at 37°C with of Proteinase K and the DNA was prepared
for PCR. PCR was performed by surrounding both NFAT1 binding sites with the following
primers;

NFATF-

GCTCAAACTGCCAGCAAAAT

and

NFATR-

CACAGGGTGTTCACAAATCG. The PCR product was run in a 1.5% agarose gel.

Reporter Constructs and Luciferase Activity Analysis
The IL-8 and MMP-3 promoters were cloned from A375SM melanoma cells to encompass
851 (IL-8) or 2682 (MMP-3) base pairs upstream of the transcriptional initiation site with the
following

primers

respectively;

IL-8
and

GGGGTACCCTGCTCTTATGCCTCCACTG-3’
GGAAGATCTCTTGTGTGCTCTGCTGTCTCT-3’

Forward-5’-

and

GGGGTACCCACTCAGTTGCTCTTTAATTTTACC-3’

for

Reverse-5’MMP-3
and

Forward-5’Reverse-5’-

GGAAGATCTCGCACAGCAACAGTAGGATTG-3’. PGL-3 basic was cut with Kpn1 and
BglII restriction enzymes and the IL-8 or MMP-3 promoters were inserted. Direct site
mutagenesis of NFAT1 binding sites were carried out using QuikChange II XL Site-Directed
Mutagenesis Kit (Stratagene) according to manufacturer’s instructions. Cells were plated in
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a 24 well plate with 2.0 x 104 cells/ well. After 48 hours, transfection with Fugin 6
(Promega) was performed according to manufacturer’s instructions. Briefly, each well was
transfected with 0.8 μg of the basic pGL3 expression vector with no promoter sequence or
with 0.8 μg of pGL3 with the inserted IL-8 or MMP-3 promoter; mutations were performed
in the NFAT1 binding sites. As a control, 2.5 ng of cytomegalovirus (CMV) driven renilla
luciferase construct (pRL-CMV, Promega) was included per well. Each group was plated in
replicates of six. After 48 hours the cells were lysed and luciferase activity was assayed with
the Dual Luciferase Reporter Assay System (Promega) according to the manufacturer’s
instructions. The ratio of PGL3 firefly to CMV-driven renilla luciferase activity was used to
normalize each sample.

Immunohistochemistry (IHC)
Mice were killed and tumors were collected. Half of each tumor was formalin fixed and
embedded into paraffin and the other half was frozen at -80°C. Paraffin-embedded tumor
specimens were mounted on positively charged superfrost plus slides (Fisher Scientific).
Slides were heated at 56°C for 20 min and de-paraffinized in xylene, hydrated in graded
ethanol (100%, 95%, and 80% ethanol), and then rehydrated in PBS twice. Antigen retrieval
was performed in pepsin (BioCare Medical) at RT for 10 minutes or with citrate buffer 0.1M.
Endogenous peroxidase was blocked with 3% hydrogen peroxide in PBS. Samples were
exposed to protein block (5% normal horse serum and 1% normal goat serum in PBS) for 20
minutes and incubated with each primary antibody – rabbit anti-human IL-8 (1:100), rabbit
anti-human NFAT1 (1:400) and rabbit anti-human MMP-3 (1:100) antibodies overnight at
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4◦C. Slides were washed, incubated for 10 minutes in protein-blocking solution, and then
reacted with goat anti-rabbit IgG secondary antibodies (Jackson ImmunoResearch, West
Grove, PA).

CD31 staining was executed by the same protocol as procedures of other antibodies, except
that a goat anti-mouse CD31 (1:200) antibody (PharMingen, San Diego, CA) was used.
Upon washing with PBS, the signals of specimens were developed with 3,3'Diaminobenzidine (DAB) for 5-10 minutes at RT. The slides were washed with dH2O, airdried and applied with cover slides. The photo images were obtained from the Leica
microscope DFC 320 (Wetzlar, Germany) For CD31 staining, frozen sections were fixed for
5 minutes in each of the following solutions: acetone, acetone:chloroform (1:1) and acetone.
Slides were then washed with PBS three times and blocked with protein block 4% Fish
gelatin in PBS for 20 minutes at room temperature. Slides were incubated at 4°C over night
with primary antibody (rat anti-mouse CD31, PharMingen Inc. Cat. #01951A). Alexa 494
[125] was incubated for 1 hour at room temperature. Slides were then washed 3 times for 3
minutes in PBS.

TUNEL assay
TUNEL staining was performed utilizing a TUNEL assay kit (Promega, Promega, Madison,
WI). Slides were fixed in 4% Paraformaldehyde for 10 minutes at room temperature followed
by two 5 minute washes with PBS. Slides were then incubated in 0.2% Triton X-100 in PBS
for 15 minutes and washed twice with PBS. Subsequently, slides were incubated with DNase
for 10 minutes at 37ºC and washed four times with PBS. Equalibrium buffer was then used

34

on slides for 10 minutes at room temperature. Incubation buffer containing 5ul Nucleotide
Mix and 1 ul of TDT enzyme was then applied on slides. Slides were then incubated at 4°C
over night. The following day, slides were washed with SSC buffer twice for 15 minutes
followed by washes with PBS to remove unincorporated Fl-dUTP. Hoechst (Molecular
Probes, Carlsbad CA) diluted at 1:10,000 in PBS was used to counterstain slides.

Animals
Female athymic BALB/c nude mice at the age of 8-10 weeks were purchased from Taconic
(Hudson, NY ). Animals were maintained in facilities approved by the American Association
for Accreditation of Laboratory Animal Care in accordance with current regulations and
standards of the United States Department of Agriculture, Department of Health and Human
Services, and the NIH. All studies were approved and supervised by The University of Texas
MD Anderson Cancer Center, Institutional Animal Care and Use Committee (IACUC).

In Vivo subcutaneous tumor growth
Subcutaneous tumors were produced by injecting 0.5-1 x106 tumor cells/100 ul PBS into the
right frank of each mouse. Between 6 to 8 mice mice were injected for each group. Tumor
size was monitored twice a week for 27 days. Mice were then sacrificed and tumors were
collected. The tumors were processed for IHC to detect alteration of IL-8, MMP-3, CD31.
TUNEL assays also were performed to determine the effects on vessel density and apoptosis
of tumors.
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Experimental Lung Metastasis Assays
For lung metastasis experiments, 6 to 8 mice per group were injected with 0.5-1x106 tumor
cells in 100 ul PBS via mouse lateral tail veins as previously described [89]. Tumor
metastasis burden was closely monitored. Any mouse that demonstrated a sign of thin or
hunched postures was scarified earlier. The mice were killed about 6 weeks after injections;
the lungs were removed, and fixed in Bouin's solution for 24 hours. The number of surface
tumor nodules were counted using a dissecting microscope.

cDNA Microarray
Total RNA was isolated from A375SM NT and NFAT1 shRNA melanoma cells using
mirVana Isolation Kit (Life Technologies). RNA was then converted into cRNA using the
Illumina TotalPrep Amplificatin Kit (Life Technologies) and hybridized to HT-12 Illumina
chip in triplicates.

Gene expression analysis was performed between NFAT1 NT and

NFAT1 shRNA samples.

Statistical Analysis
Student's t test was used to analyze the statistical significance of differences in the in vitro
data. In the animal studies Mann-Whitney U test was used in the tumor growth and lung
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metastasis results. Values for tumor growth are given as a mean volume ± S.E.M. P values
that are smaller than 0.05 were considered statistically significant.

TCGA Analysis
Statistical analyses were performed in R (version 3.0.1) (http:///www.r-project.org/) and the
statistical significance was defined as a p-value less than 0.05. We downloaded and analyzed
clinical and mRNA (Level 3 Illumina RNASeqv2) data publicly available from the Cancer
Genome Atlas Project (TCGA; http://tcga-data.nci.nih.gov/) for patients with skin cutaneous
melanoma (SKCM).
For NFAT1 Tumor vs. Metastatic comparison
The Shapiro-Wilk test determined that NFAT1 (log2 reads) did not follow a normal
distribution in tumor or metastatic samples.

The nonparametric test Mann-Whitney-

Wilcoxon test was applied to compare NFAT1 expression levels between the two groups and
a box-and-whisker plot (Box plot represents first [lower bound] and third [upper bound]
quartiles, whiskers represent 1.5 times the interquartile range) was used to visualize the data.
For survival IL-8 and MMP-3:
For each gene of interest, we checked for a relation with the survival as follows. Patients
were grouped into percentiles according to mRNA expression. The Log-rank test was
employed to determine the association between mRNA expression and overall survival and
the Kaplan-Meyer method was used to generate survival curves. Cut-off points (log-rank test
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p-value <0.05) to significantly split the samples into low/high mRNA groups were recorded.
The cut-off to optimally separate the patients in high/low (min p-value) was chosen.

Dual IHC Staining for Tissue Microarray (TMA)
Paraffin sections in 5 μm thickness were made, and immunohistochemistry was performed
using monoclonal antibodies against NFAT1 (clone D43B1 [1:50 dilution]; Cell Signaling,
Danvers, MA) and CD8 (Clone C8/144B [1:20 dilution]; LabVision, ThermoFisher). After
deparaffinization, antigen retrieval was performed using a citrate buffer (pH 6.0) in a
pressure cooker. Slides were then incubated with NFAT1 antibody, followed by Envision+
horseradish peroxidase reagent (Dako, Carpentaria, CA), followed by incubation with
diaminobenzidine (DAB). After washing, the slides were incubated with CD8 antibody,
followed by an alkaline phosphatase-conjugated secondary antibody (Bond Polymer Refine
Red Detection, Leica Biosystems, Buffalo Grove, IL), and then incubated with Fast Red/AP
chromogen. CD8 (red chromogen) and NFAT1 (brown chromogen) immunoreactivity were
considered positive if moderate to strong staining was identified in even a single cell. The
extent of staining was quantified using the following scale: 0 indicated no staining; 1+
indicated positive reactivity in < 25% of tumor cells; 2+ indicated positive reactivity in 2550% of tumor cells and 3+ indicated positive reactivity in > 50% of tumor cells. Localization
to the cytoplasm or the nucleus was recorded for all cases expressing NFAT1. CD8 localized
to the cytoplasm & membrane when expressed. The TMA that we have used have total 130
specimens: 59 Nevi, 39 primary and 32 metastatic, each sample is represented twice on the
block.
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CHAPTER 3: Specific Aim 1

To Determine the Status and Contribution of NFAT1 to Melanoma Progression
1.1 Examine the Status of NFAT1 in Melanoma Progression
1.2 Study the In Vitro and In Vivo Effects of Silencing NFAT1 in Metastatic Melanoma
Cell Lines and the Effects of Overexpression NFAT1 in Low Metastatic Cell Lines

Introduction
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Melanoma is the deadliest form of skin cancer in the United States [2]. During the
last decade there has been tremendous progress in understanding the genetic changes that are
associated with melanoma progression. Those newly discovered target genes can potentially
help researchers in finding new therapeutic combinations in melanoma. During the
progression of the disease, melanoma cells need to acquire the ability to invade the basement
membrane and migrate into the dermis. In our research, we are looking at NFAT1 as a
potential gene that may be an important protein that helps melanoma cells acquire the
invasive phenotype. NFAT1 expression has also been associated with cancer; in breast
cancer patient specimens, higher expression of NFAT1 was recognized with primary tumors
and lymph node metastasis compared to normal adjacent tissue [112]. By evaluating past
publications and previous evidence we hypothesized that NFAT1 (besides its role in the
immune system) can be a key player in the invasive phenotype of melanoma cells. NFAT1 is
possibly playing an important role in melanoma progression and metastasis formation. In this
first specific aim we want to determine the contribution of NFAT1 to the In vitro and In vivo
phenotype of melanoma cell lines and examine the status of NFAT1 in melanoma patients.
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Sub Aim 1.1: Examine the Status of NFAT1 in Melanoma Progression (Cell Lines and
Patients)

Results
Analysis of NFAT1 Expression in a Melanoma Cell Line Panel
To examine the status of NFAT1 in melanoma progression, a panel of melanoma
lines ranging from low to highly metastatic were utilized. Using western blot analysis, we
validated that the more metastatic cell lines they express higher levels of NFAT1, while the
less metastatic melanoma cells express significantly lower levels of NFAT1. As shown in
figure 4, the highly metastatic melanoma cell lines (Mewo, TXM18, A375SM WM2664 and
41

WM902B) expressed higher levels of NFAT1 as compared to the less metastatic melanoma
cell lines (SB2, and DM4). Our cell panel can be further divided into two groups: those with
BRAF mutations (highly metastatic in our case) and those with NRAS mutations (low
metastatic in our case). When NFAT1 expression was analyzed by this manner, we found
that cells with BRAF mutations have higher expression levels of NFAT1 and cell lines with
the NRAS mutations had a lower expression of NFAT1. However, it is possible that this cell
line panel is not representative. A larger scale analysis should be performed in order to have
a conclusion about the connection between the BRAF mutations with NFAT1 expression
levels in melanoma cell lines. Therefore this correlation could be due to the panel lacking
highly tumorigenic NRAS and non BRAFV600E mutation cell lines. Later, we also performed

Low

Highly

metastatic

metastatic

WM902B

WM2664

A375SM

TXM18

Mewo

DM4

SB2

patients analysis for NFAT1 to confirm.

Figure 4: NFAT1 is Expressed at Higher Levels in Metastatic Human Melanoma Cell Lines
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Western blot analysis in melanoma cell lines was performed. The less tumorigenic SB2, and DM4
melanoma cell lines express significantly less NFAT1 than the more tumorigenic and metastatic
Mewo, TXM-18, A375SM, WM2664 and WM902B cells.

Melanoma TCGA Analysis of NFAT1
In this set of experiments we sought to validate our observations in melanoma cell lines by
mining the TCGA (The Cancer Genome Atlas) data for NFAT1 expression. This analysis
revealed a significant higher expression of NFAT1 in metastatic lesions compared to primary
melanoma lesions (p=0.0079) (Figure 5). This analysis validated our observation in
melanoma cell lines that, the more metastatic the cell is, the higher NFAT1 expression it has.
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Figure 5: Analysis of TCGA Melanoma Data for the Expression of NFAT1 in Melanoma
Patients Analysis of TCGA revealed a significant overexpression of NFAT1 in the metastatic lesions
(p=0.0079) compared to primary melanoma lesions. Primary melanoma lesions (n=55), metastatic
lesions (n=257).
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Analysis of NFAT1 in a Melanoma Patients’ Tissue Microarray (TMA)

To further delineate the status of NFAT1 in melanoma progression, the expression of NFAT1
was examined in tissue samples from melanoma patients in different stages (nevi, primary
and metastatic). The evaluation was made in a way that the score is given by the expression
level of NFAT1 on the tumor cells but not on the immune cells. This scoring was achieved
after double staining for NFAT1 and tumor infiltrating lymphocytes (TIL). The expression
was evaluated on the tumor cells alone. CD8 (red stain for T cells) and NFAT1 (brown)
immunoreactivity were considered positive if moderate to strong staining was identified. For
quantification we used the following scale: 0 indicated no staining; 1+ indicated positive
reactivity in < 25% of tumor cells; 2+ indicated positive reactivity in 25-50% of tumor cells
and 3+ indicated positive reactivity in > 50% of tumor cells. Indeed there was a difference
between the expression of NFAT1 in metastatic versus primary melanoma patients. The
metastatic tissues expressed more NFAT1. Unfortunately, the scoring is still in progress but
from the general trend we can assume that these results support the TCGA analysis and the
results from the western blot for the cell panel.
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Figure 6: Analysis of TMA for the Expression of NFAT1 in Melanoma Patients. On this
array there are 130 human tumor samples. After scoring the expression of NFAT1 on tumor
cells we can see a significant difference between metastatic and primary melanoma tumors.
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Sub Aim 1.2 Study the In Vitro and In Vivo Effects of Silencing NFAT1 in Metastatic
Melanoma Cell Lines and the Effects of Overexpression NFAT1 in Low Metastatic Cell
Lines

Results
The Effect of Silencing NFAT1 in metastatic melanoma and overexpressing it in low
metastatic melanoma cell lines.
To establish the role of NFAT1 in melanoma progression and in promoting tumor
growth and metastasis, we chose to stably silence NFAT1 in two metastatic melanoma cell
lines that have high levels of NFAT1 expression and overexpressing NFAT1 in a low
metastatic cell line (with low levels of NFAT1). From our cell line panel, the cells that met
these criteria were the WM902B, A375SM and SB2 melanoma cell lines (Figure 4). The two
metastatic melanoma cell lines, A375SM and WM902B, were then stably transduced with
non-targetable (NT) or NFAT1 shRNA packaged lentivirus. NT shRNA has no known
homolog sequence among human genes; it will be used as a control to verify that the
transduction by the virus itself did not cause any unexpected changes in the cells. This
control vector contains green fluorescent protein (GFP) and it will be used throughout the
study. The SB2 cell line was stably transduced with the NFAT1 overexpression construct and
for the control we used an empty vector (EV) construct that does not include any inserted
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gene. The overexpression transduction has a puromycin selection, and in order to select the
positively transduced cells, the culture was grown with 1mg/ml puromycin for 48hr. For
A375SM and WM902B, both NT and NFAT1 shRNA melanoma cells were sorted for the
top 40% percent of GFP fluorescence, by Fluorescent Activated Cell Sorting (FACS). After
cell sorting/puromycin selection, WM902B, A375SM and SB2 melanoma cell lines that were
transduced were expanded in culture. We performed western blot analysis to determine the
silencing efficiency of NFAT1 shRNA or the overexpression efficiency for NFAT1 overexpressing vector. By using densitometry and normalizing NFAT1 to actin, it was observed
that the WM902B and A375SM cell lines have 58% and 75% knock down of NFAT1
respectively as compared to the NT shRNA control (Figure 7). In SB2 cells, NFAT1
overexpression results demonstrated infinite fold of NFAT1 overexpression in that cell line
due to no expression in the parental cells. These three cell lines were then used throughout
the study.
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Figure 7: Stable Transduction of NFAT1 shRNA/ Overexpressing Vector Efficiently Reduce
NFAT1 Expression in both WM902B and A375SM and Overexpress it in SB2 Melanoma Cell
Lines. NFAT1 expression is lost in both melanoma cell lines with the stable lentiviral based
transduction of NFAT1 shRNA.

Densitometry analysis for WM902B cells confirms that

approximately 58% of NFAT1 expression is lost. For A375SM cells, NFAT1 expression is 75% lost.
For SB2 cells we have a complete overexpression of NFAT1.
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In Vitro Invasive Phenotype of Melanoma Cells Following NFAT1 Silencing/
Overexpression
To validate that NFAT1 increases the invasive phenotype of melanoma cell lines,
NFAT1 silenced WM902B and A375SM melanoma cells and SB2 with NFAT1
overexpression were subjected to the matrigel invasion chamber invasion assay. The cells
were plated in fetal bovine serum (FBS) free media (MEM) on top of the chamber. The cells
were incubated for 24 hours. The bottom chamber contained MEM media with 20% FBS to
act as a chemoattractant. The number of invaded cells through the chamber was evaluated by
counting equal fields from all membranes. A significant reduction in the number of invaded
melanoma cells was observed after silencing NFAT1 in both WM902B and A375SM cell
lines, *p < 0.001 (Figure 8). A more than 2 fold reduction was observed in WM902B cells
and more than 3 fold reduction in A375SM. A significant increase in the number of invaded
cells was observed after overexpression of NFAT1 in SB2 cells; more than a 5 fold increase
was observed. As seen in figure 8, the invasive capacity of melanoma cells is significantly
reduced after silencing NFAT1 in metastatic cell lines p < 0.001, with more than a 2 fold
reduction in WM902B and 3 fold reduction in A375SM, and on the other hand, the invasive
capacity was increased after NFAT1 overexpression in SB2 cells. Therefore, our data support
the idea that NFAT1 is critical for the invasive phenotype of melanoma cell lines. To make
sure that the invasive phenotype indeed changed as a result of NFAT1 expression in the cell
lines and not due to higher doubling time of the tested cells, we performed MTT proliferation
assay as presented in figure 9. We found no changes in the doubling time of A375SM and
WM902B after NFAT1 silencing compare to the NT. Similar results were observed in this
the SB2 cell line after overexpression of NFAT1. Since no significant difference was
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detected in the doubling time, we concluded that the changes in the invasion assay were not
due to differences in cell division times but due to NFAT1 genetic manipulations which
influenced on the invasive and migratory phenotype.
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A.

B.
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Figure 8: The Invasive Phenotype of Melanoma Cells after Silencing /Overexpressing NFAT1
The invasive phenotype of melanoma cells were analyzed by matrigel invasive chambers 8µm (A)
The number of invaded cells through the Matrigel invasion chamber is significantly reduced after
silencing NFAT1 in both WM902B and A375SM melanoma cells as compared to NT shRNA (*P <
0.001) and on the other side, the number of invaded cells is significantly increased after NFAT1
overexpression in SB2 cells. (B) A representative image for each cell line with either NT or NFAT1
shRNA or NFAT1 overexpression is shown (NT non targeting, OE overexpression).
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Figure 9: Proliferation Rate of NFAT1 Silenced Metastatic Melanoma Cell Lines or NFAT1
Overexpression in Low Metastasis Cell Lines. MTT assays were performed to determine doubling
time of A375SM, WM902B (A,B) cells after transduction with NFAT1 shRNA as compared to NT
transduced cells, and SB2 after NFAT1 overexpression compared to empty vector control (C). MTT
assays determined relative cell numbers based on the conversion of MTT to formazan in viable cells.
Cell growth was measured daily for 5 days period. No significant differences were found in the
doubling time in either transduced cell line (P>0.05).
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Determine the In Vivo Effect NFAT1 on Tumor Growth and Experimental Lung
Metastases
To determine whether NFAT1 has an effect on melanoma tumor growth and
metastasis, an in vivo experiment was performed. To that end, we used A375SM highly
metastatic cells with NFAT1 shRNA compared to NFAT1 NT shRNA and the low metastatic
SB2 after NFAT1 overexpression compared to SB2 EV (empty vector). 5x105 A375SM cells
or 1x106 SB2 cells were injected subcutaneously into the right flank of nude mice (n=6 mice
per group) for tumor growth, or intravenously into the tail vein of the mice (n=6 mice per
group) for experimental lung metastases. Each group had the control group A375SM NT and
SB2 EV respectively. The subcutaneous tumors were monitored twice weekly for 31 days for
A375SM, and for 41 days for SB2 cell lines. At the end of the measurements the tumor size
mean of A375SM NT group was 1557mm3 compared to 509mm3 in the A375SM with
NFAT1 shRNA (Figure 10A). At day 41, SB2 EV cells had a mean tumor volume of
428mm3 compared to 1125mm3 for SB2 NFAT1 OE cells (Figure 10B). We observed a
significant decrease in tumor growth after silencing NFAT1 and significant increase in tumor
growth after overexpressing NFAT1 in melanoma cells. Since we already demonstrated that
there is no difference in the doubling time of these cell lines, we can conclude that the
differences we observed in tumor growth rates are due to NFAT1 expression.
For the experimental lung metastasis, A375SM were injected in two groups NT and
NFAT1 shRNA as well as SB2 EV cells and SB2 NFAT1 OE cells. After 6 weeks, the mice
were killed and macroscopic lung metastases were counted in all groups. The results showed
that the number of lung metastases was significantly decreased after silencing of NFAT1
(mean of 10 mets) in the highly metastatic A375SM cells when compared to the A375SM
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NT group (mean of 36.17 mets) (Figure 10C), and conversely, the number of lung metastases
was significantly increased in the SB2 NFAT1 OE group (mean of 36 mets) compared to
SB2 NFAT1 EV (mean of 11 mets) as presented in figure 10D. The mean number of lung
colonies of A375SM groups were 36 for NT and 10 for NFAT1 shRNA p<0.01 and 11 for
SB2 EV and 36 for SB2 NFAT1 OE p<0.001.
Taken together, NFAT1 silencing, which was achieved through lentiviral shRNA, resulted in
an inhibition of experimental lung metastasis growth of A375SM metastatic melanoma cells.
Furthermore, overexpression of NFAT1 in the low metastatic cell line, SB2, resulted in an
increase of lung metastasis growth, thereby strengthening our hypothesis that NFAT1 is
essential to melanoma growth and metastasis.
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Figure 10: NFAT1 Expression is Required for the Malignant Melanoma Phenotype
Silencing NFAT1 in A375SM melanoma cells reduces tumor growth and experimental lung
metastasis in nude mice while overexpression of NFAT1 in SB2 increases both tumor growth and
metastasis. (A) A375SM melanoma cells were injected subcutaneously in nude mice and tumor
growth was monitored for 31 days. Tumor growth was significantly reduced after silencing NFAT1
at day 31, tumor volume mean of 1557mm3 compared to 509mm3 (*P < 0.05). (B) SB2 melanoma
cells were injected subcutaneously into nude mice and monitored for 41 days. Tumor growth was
significantly increased after overexpressing NFAT1, mean tumor volume of 428 mm3 compared to
1125 mm3 (*P<0.05) (C) Six weeks after intravenous injection of A375SM cells, nude mice were
sacrificed and the number of lung metastasis were counted. Silencing NFAT1 significantly reduced
the number of experimental lung metastasis, mean of 10mets compared to 36 mets (P* < 0.01). (D)
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Six weeks after intravenous injection of SB2 cells, nude mice were sacrificed and the number of lung
metastasis was counted. Overexpressing NFAT1 significantly increased the number of experimental
lung metastasis mean of 36 mets compared to 12 mets (P* < 0.001).
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Silencing NFAT1 Changes the Gene Expression Profile of A375SM Melanoma Cells

To identify potential downstream targets of NFAT1, an Illumina microarray was
performed (HT-12 Version 3 chip). RNA from three separate 10cm dishes (to confirm
reproducibility) was isolated from A375SM NT and NFAT1 shRNA cells. Our data suggest
that silencing NFAT1 does deregulate various genes in these melanoma cells. We then
mined the data to identify novel genes with significant fold changes in the gene expression
array. We focused our attention on genes that were down regulated after silencing NFAT1,
since they were likely to be tumor promoter genes. The top identified genes then were mined
and sorted by their relevance to cancer are presented in Table 1. Among these genes that
were downregulated after NFAT1 silencing, we found follistatin (FST) that has been reported
as a contributor to bone metastasis [126] and placenta-specific 8 (PLAC8) whose
overexpression is reported to protect cancer cells from apoptosis [127-129]. Also, frizzeld
family receptor 4 (FZD4), nicotinamide N-methyltransferase (NNMT). Of the potential
genes, we decided to focus our research on interleukin 8 (IL-8/CXCL8) and matrix
metallopeptidase 3 (MMP-3). IL-8 is known to play an important role in the progression and
metastasis of several different cancers including melanoma. Our laboratory has previously
demonstrated that overexpression of IL-8 is associated with increasing tumor stage, disease
progression, and recurrence in human melanoma. Furthermore, a direct correlation between
high levels of IL-8 and tumor angiogenesis, progression, and metastasis in nude mouse
xenograft models of human melanoma were previously shown [130]. Therefore, we
hypothesize that NFAT1 may contribute to melanoma tumor growth and metastasis through
the regulation of IL-8. The second gene that we decided to study as a downstream target of
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NFAT1 is MMP-3. MMP-3 was shown to be associated with Alzheimer’s, multiple sclerosis
and Parkinson’s disease. MMP-3 also contributes to several pathologies such as asthma,
rheumatoid arthritis and cancer [131]. MMP-3 transcription can be triggered by reactive
oxygen species (ROS), cytokines, growth factors and cell interactions. MMP-3 can activate
cell adhesion molecules, growth factors, chemokines, cytokines and receptors. Likewise,
MMP-3 is able to activate other MMP family members. In melanoma MMP-3 has not been
much studied, and the role of MMP-3 in melanoma progression has yet to be elucidated,
therefore we decided to study the role of MMP-3 in the metastatic melanoma phenotype.
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Table 1: Top Potential Genes Down Regulated after Silencing NFAT1
The top potential candidate genes are shown. These genes were downregulated after silencing
NFAT1 in A375SM melanoma cells as compared to the non-targeting (NT) control. Note that our
gene expression array confirmed that after NFAT1 silencing, autotaxin was reduced by almost 3 fold
as was published by our lab before [122]. The two genes of interest IL-8 and MMP-3, are
downregulated by 2.4 and 3.22 fold respectively.
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Summary Specific Aim 1
Herein, we report that there is a positive correlation between the metastatic potential
of the melanoma cell lines and the expression level of NFAT1. The more metastatic the cell
is, it correlates with higher NFAT1 expression level. Furthermore, from TCGA data analysis,
we found that specimens from metastatic patients demonstrated significantly higher
expression of NFAT1 compared to patients with primary tumors. These results support our
observations in the cell lines. We validated these results by staining our own in house TMA.
Also, we showed that silencing NFAT1 in two metastatic melanoma cell lines, WM902B and
A375SM, significantly reduced the invasive potential of these cell lines, while
overexpression of NFAT1 increases the invasiveness of SB2 cells; although these
manipulations did not change the proliferation ability of the cell lines. The role of NFAT1 in
melanoma tumor growth and experimental metastasis was also examined by utilizing an in
vivo study. The in vivo studies confirmed that the expression of NFAT1 in the melanoma
cells is important for the progression of the disease. In the presence of NFAT1 the tumor
growth and the number of experimental lung metastasis were higher. After confirming that
NFAT1 is necessary for the metastatic potential of the cells, we performed gene expression
profiling in an attempt to identify potential NFAT1 downstream target genes that might be
playing important roles in melanoma progression. In the next chapter we will concentrate on
the link between NFAT1 regulation of IL-8 and MMP-3 expressions.
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CHAPTER 4: Specific Aim 2

To Identify Novel NFAT1 Downstream Target Genes that Contribute to the Metastatic
Melanoma Phenotype

2.1 Study NFAT1 as a Potential Regulator of IL-8 Expression in Melanoma Cells
2.2 Study NFAT1 as a Potential Regulator of MMP-3 Expression in Melanoma Cells
2.3 Determine the Contribution of MMP-3 to Melanoma Growth and Metastasis

Introduction
We have demonstrated that NFAT1 silencing in A375SM significantly reduced tumor
growth and experimental metastasis in vivo when compared to the NT control group (Figure
10 A,C). We have also demonstrated that overexpressing NFAT1 in the low metastatic SB2
cells increased their invasion in vitro as well as incresed tumor growth and their metastastic
potential in vivo (Figure 10 B,D) . Next we wanted to identified downstream target genes of
NFAT1 and determine the mechanism by which NFAT1 regulates these genes. From cDNA
microarray studies, we identified that NFAT1 silencing in A375SM resulted in a significant
decrease of several downstream gene targets as presented in Table 1. These genes may
contribute to the metastatic phenotype of melanoma. Among these genes that were
downregulated after NFAT1 silencing we found follistatin (FST), which has been reported as
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a contributor to bone metastasis [126], placenta-specific 8 (PLAC8), whose overexpression is
reported to protect cancer cells from apoptosis [127-129]. Also frizzeld family receptor 4
(FZD4), nicotinamide N-methyltransferase (NNMT) and others were downregulated. In our
research we decided to concentrate on two genes that were downregulated after NFAT1
silencing, interleukin 8 (IL-8) and matrix metallopeptidase 3 (MMP-3). Previous data
indicated that NFAT1 can have a major effect on the transcriptional regulation of a variety of
genes. In breast cancer it was found that NFAT1 promotes breast cancer cell invasion
through the induction of COX-2 [114]. In breast cancer it was also found that there is a
negative cross talk between Stat5 and NFAT1 signaling cascades, which may affect breast
tumor growth and metastasis [112]. NFAT1 has also been shown to support tumor induced
anergy of CD4+ T cells [119]. In this aim, we wanted to identify novel downstream genes
regulated by NFAT1 that may contribute to melanoma growth and metastasis. To that end, a
gene expression microarray (Illumina) was performed. Our microarray data has identified
many potential target genes including IL-8 and MMP-3 and many others. The regulation of
IL-8 and MMP-3 by NFAT1 has not been described yet. Therefore, we chose to concentrate
on these two target genes and clarify the link between NFAT1, IL-8 and MMP-3 and their
contribution to melanoma progression.
Unfortunately, increasing melanoma incidence has led to a growing number of patient
deaths due to the aggressive nature of melanoma which commonly metastasizes to the lymph
nodes, lung, liver, and brain [132, 133]. Currently, less than 10% of patients presented with
malignant melanoma survive longer than 5 years [2]. Therefore, other treatment modalities
besides targeting BRAF are needed. Of note, more than 50% of melanoma patients do not
harbor the BRAFV600E mutation.
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One of these potential molecules is the chemokine IL-8 (CXCL8). It has been shown
that IL-8 expression is positively correlated with melanoma progression [134-136].
Chemokines are 8-14 kDa signaling proteins that bind to their seven membrane spanning G
protein-coupled receptors. Chemokines are classified by the position of two conserved cys
residues at the N-terminal. These families include the CXC, CC, C, and CX3C chemokines
[134]. IL-8 is a 8-kDa protein that belongs to the CXC chemokine family. Chemokines were
initially identified as chemoattractants for leukocytes, however, their expression and
corresponding receptors have been observed in multiple cell types [134]. In melanoma, IL-8
was the first chemokine shown to facilitate cancer cell migration. The overexpression of IL8 in melanoma cells up-regulates the expression and activity of the matrix metalloproteinase
MMP-2, which in turn contributes to a more invasive phenotype [137]. IL-8 binds to its
receptors CXCR1 and CXCR2 (located on both melanoma and endothelial cells), thus
promoting tumor growth and angiogenesis [137-140]. Due to the pro-tumorigenic and
survival- dependent effects of IL-8 in cancer, targeting IL-8 could be therapeutically
beneficial for melanoma patients. Previously our lab has shown that neutralizing IL-8 with a
fully human antibody, ABX-IL8, can significantly reduce tumor growth and experimental
metastasis of A375SM and TXM-13 melanoma cells [141]. IL-8 has been shown to promote
the growth, invasiveness, motility, angiogenesis, and metastatic potency of melanoma cells
[137, 141-143]. Furthermore, our lab has also demonstrated that neutralizing IL-8 ABX-IL-8
inhibited melanoma growth and metastasis in vivo, mostly by inhibiting angiogenesis [141].
Interestingly, targeting IL-8 reduced MMP-2 expression, and incubation of melanoma cells
with ABX-IL-8 reduced the invasive potential of melanoma cells through Matrigel coated
membranes. Decreased CD31 staining in vivo and HUVEC tube formation in vitro was also
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observed [141]. In a new study in the lab, we utilized a siRNA delivery approach to silence
IL-8 to reduce melanoma growth and metastasis in vivo. In the present study we want to
further understand the regulation mechanism of IL-8 during melanoma progression by the
NFAT1 transcription factor.
Matrix metalloproteinases (MMPs) are a family of zinc-dependent proteases. The
proteins in this family have the ability to degrade extracellular matrix components such as
collagen, gelatin, elastin and casein [144]. Matrix metalloproteinase 3, (MMP-3) which is
also known as stromelysin-1, is a member of the MMP family. It is known to cleave
extracellular components including different types of collagens ( types III, IX, and X) [145].
MMP-3 has been associated with Alzheimer’s, multiple sclerosis and Parkinson’s disease.
MMP-3 also contributes to several pathologies like asthma, rheumatoid arthritis and cancer
[131]. MMP-3 transcription can be triggered by reactive oxygen species (ROS), cytokines,
growth factors and cell interactions. MMP-3 has many substrates. Besides extracellular
matrix (ECM) proteins, it can activate cell adhesion molecules, growth factors, cytokines,
chemokines, cytokines and receptors. Likewise, MMP-3 is able to activate other MMP
family members. Secreted MMP-3 can be activated extracellularly and then transported back
into the cell [131]. In melanoma, MMP-3 was investigated as a potential serum marker and
the levels of MMP-3 in the serum were evaluated between healthy patients and malignant
melanoma patients, but no significant difference was found [146, 147].
Melanoma progression is a multistep cascade, which requires chemokines, angiogenic
factors, adhesion molecules and proteases. Several studies suggested that the metastatic
potential of melanoma is influenced by elastin, which is considered to be one of the most
important ECM components, especially on the wall of blood vessels and in the lung. MMP-2
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and MMP-3 degrade elastin proteins, and overexpression of these two genes is correlated
with aggressive melanoma and poor clinical outcome [148, 149]. It was shown that higher
stage melanoma is associated with higher levels of elastin, and that the interactions between
the elastin peptides and the melanoma cells are key for melanoma progression [148, 150].
Another study in the field reported that Angpt2, MMP-3 and MMP-10 are all upregulated in
the lung due to the primary B16F10 tumor in mice [151]. The lung microenvironment could
be critical for presenting the pre metastatic niche that resulted from the influence of the
primary tumor. Further, it has been shown that Angpt2, MMP-3 and MMP-10 have a
synergistic effect on vascular destabilization that promotes the extravasation of melanoma
cells and supports lung metastasis [151].

Recently SOX2, an embryonic stem cell

transcription factor, was found to be expressed in human melanoma cells [152, 153]. It was
also found that after silencing SOX2 in melanoma cells, the expression of MMP-3 was
reduced by almost 90% [154]. From the association between SOX2 and MMP-3 it was
evident that MMP-3 is regulated by SOX2 and that their co-expression may be used as a
functional biomarker for invasive melanoma cells [154].
As per our knowledge, this study is the first to identify that NFAT1 is a positive
regulator of MMP-3 and IL-8 expression in melanoma, thus adding a posible mechanism of
how NFAT1 contributes to melanoma progression. Furthermore, this is the first study to
demonstrate the importance of MMP-3 in melanoma growth and metastasis.
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Sub Aim 2.1: Study NFAT1 as a Potential Regulator of IL-8 Expression in Melanoma
Cells

Results
IL-8 Expression is Reduced in Melanoma Cells after Silencing NFAT1, and Increased
after Overexpressing NFAT1
To validate our gene expression microarray, qRT-PCR and ELISA assays were performed.
To identify IL-8 expression, the A375SM and WM902B highly metastatic melanoma cells
were transduced with NT or NFAT1 shRNA while the SB2 low metastatic cell line was
transduced with EV and NFAT1 overexpression. To check that the downstream targets are
not changing due to off target effects after transduction we also performed rescue experiment
where the cells containing NFAT1 shRNA were transduced with an NFAT1 rescue vector
(Figure 11). The rescue construct does not contain the sequence recognized by the NFAT1
shRNA. As seen in figure 11, stable transduction of A375SM and WM902B NFAT1 KD
cells with NFAT1 rescue vector, NFAT1 expression levels were upregulated. Silencing of
NFAT1 in both melanoma cell lines, A375SM and WM902B, resulted in ~25% decrease in
mRNA expression of IL-8 (Figure 12 A,B). IL-8 mRNA expression was observed to be
reverted to initial levels and even more so when the rescue of NFAT1 experiment was
performed in both cell lines. In SB2 cells that were overexpressed with NFAT1 we noticed a
significant increase in mRNA levels (~100 fold) compared to the EV control group (Figure
12C). Since IL-8 primarily a secreted protein, this can be an explanation for why the whole
cell lysate western blots did not detect IL-8. Therefore, the supernatant of melanoma cells
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was collected from all three manipulated cell lines after 48hr incubation in serum free media
and was subjected to ELISA assay. As shown in Figure 13, silencing NFAT1 significantly
reduced the amount of IL-8 within the supernatant by ~ 4 fold in WM902B cells and ~2.5
fold in A375SM cells (Figure 13). Also, IL-8 protein levels were significantly increased in
SB2 cells after NFAT1 overexpression compared to the EV control by more than 10 fold.
These results from the ELISA assay show that the protein was correlated to the mRNA levels
of IL-8 after NFAT1 silencing or NFAT1 overexpression as presented in figure 12. In figure
11, the western blot from the rescue experiment is presented. In both A375SM and WM902B
cell lines, we can see clearly more than 5 fold rescue of NFAT1 compare to the actin
expression. Taken together we conclude that IL-8 is being regulated by NFAT1 both at the
mRNA and protein level and that rescue of NFAT1 in NFAT1 silenced cells also rescues the
expression of IL-8.
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Figure 11: Rescue Experiment of NFAT1
In order to make sure that the effects of NFAT1 silencing is not a result of off target influence due to
the virus transduction we utilized rescue cell lines for A375SM and WM902B. These cell lines were
used to check downstream targets IL-8 and MMP-3 to see that indeed rescue of NFAT1 is also
rescuing the expression of the downstream targets.

The western blot demonstrated NT (control),

NFAT1 shRNA, then the EV, which represents the control for the overexpression vector that was
transduced into the silenced cells and then the rescue of the expression of the NFAT1 and last the
NFAT1 RES. In both cell lines we can see clearly more than a 5 fold rescue of NFAT1 compared to
the actin expression (NFAT1 140KDa, β actin 42KDa).
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Figure 12: Relative mRNA Expression of NFAT1, IL-8 and MMP-3. Real time PCR results
showing the relative expression change in the mRNA levels of the downstream targets after
manipulating NFAT1, silencing it and rescuing it. Genes that were checked are NFAT1, for
manipulation verifications, and both downstream targets IL-8 and MMP-3 (A) A375SM melanoma
cell line (B) WM902B melanoma cell lines (C) SB2 cell lines after overexpression of NFAT1
compared to the control.
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Figure 13: Rescue of NFAT1 Rescues the Protein Levels of Secreted IL-8. ELISA assay for the
secreted protein IL-8. Results demonstrate that after NFAT1 silencing; the levels of IL-8 are
downregulated and when we rescued the expression of NFAT1 the levels of IL-8 are also rescued in
both A375SM and WM902B melanoma cell lines. SB2 overexpressing NFAT1 caused upregulation
of IL-8 expression.
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NFAT1 Enhances the Promoter Activity and Expression of IL-8
To further understand the mechanism by which NFAT1 is regulating IL-8 we performed
ChIP assays to verify the binding of NFAT1 to the promoter of IL-8. First, we identified a
binding site of NFAT1 on the IL-8 promoter at 32 base pairs from the transcription initiation
site (TIS). We expect that the reduced IL-8 mRNA and protein expression after silencing
NFAT1 will be a result of NFAT1 not binding to the IL-8 promoter. To that end, we tested
whether NFAT1 binds to the IL-8 promoter and if silencing or overexpressing NFAT1
affects the binding, by utilizing the chromatin immunoprecipitation (ChIP) assay. We used
an anti-NFAT1 antibody to IP DNA-NFAT1 complexes in our engineered melanoma cells
(A375SM, WM902B NT/NFAT1 shRNA and SB2 NFAT1 EV and OE). End point PCR
was performed on the area surrounding the region of NFAT1 binding site on the IL-8
promoter. As shown in Figure 14A, NFAT1 binds to the promoter of IL-8 in both A375SM
and WM902B melanoma cell lines. When NFAT1 is silenced, no binding to the IL-8
promoter was detected in both melanoma cell lines. Also, when NFAT1 was overexpressed
in SB2, we observed a strong band demonstrating the binding of NFAT1 to the binding site
(Figure 14A).
The chromatin immunoprecipitation confirms that NFAT1 indeed binds to the IL-8 promoter.
NFAT1 binding is lost after silencing in A375SM and WM902B and a gain in binding was
observed in the SB2 cells after overexpressing NFAT1. To elucidate the role of NFAT1 in
regulating IL-8 at the transcriptional level, a dual luciferase promoter assay was used. The
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assay was designed in a way that the IL-8 promoter was cloned in front of the luciferase. The
promoter was designed with and without mutations in the IL-8 promoter binding site at
location 32. Silencing NFAT1 resulted in ~40% reduction of luciferase activity with the wild
type promoter (Figure 15A,B). When the mutated promoter was inserted into NT shRNA
melanoma cells, the luciferase activity was reduced to ~50% of the wild type promoter. The
mutation also had an effect on luciferase activity in NFAT1 silenced melanoma cells as
compared to the wild type promoter (Figure 15 A,B). Therefore, we concluded that our
reduced promoter activity (after silencing NFAT1) is a direct result of reduced binding of
NFAT1 protein to the IL-8 promoter. Overexpression of NFAT1 in SB2 resulted with a
significant increase in the IL-8 promoter activity (Figure 15 C).
Our initial microarray and qRT-PCR studies confirmed that NFAT1 regulates IL-8
expression at the mRNA level. ELISA assay demonstrated that the secreted protein levels are
also regulated by NFAT1.

Furthermore, we also demonstrated that NFAT1 is directly

binding to the IL-8 promoter by ChIP and Luciferase assays.
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A.

B.

Figure 14: NFAT1 binds to the Promoter Region of IL-8 (A) Chromatin immunoprecipitation of
NFAT1 on the IL-8 promoter is lost when NFAT1 is silenced in A375SM and WM902B cells,
binding is increased when NFAT1 is overexpressed in SB2 cells (B) One NFAT1 binding site is
located on the IL-8 promoter within the first 100bp of the transcription initiation site. (red square
represent NFAT5 binding site)
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Figure 15: Dual Luciferase Promoter Activity is Reduced in the Presence of NFAT1 Binding
Site Mutations. (A,B) Silencing NFAT1 in both A375SM and WM902B significantly reduced the
luciferase promoter activity of the wild type promoter by approximately 50% as compared to NT
shRNA ; P < 0.05. Mutating NFAT1 binding site at location 32 resulted in reduced promoter activity
to at least 50% of the wild type promoter; P < 0.05. (C) NFAT1 overexpression in SB2 cells increased
luciferase promoter activity.
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Sub Aim 2.2: Study NFAT1 as a Potential Regulator of MMP-3 Expression in
Melanoma Cells

Results
MMP-3 Expression is Reduced in Melanoma Cells after Silencing NFAT1 and
Increased after Overexpressing NFAT1
To identify downstream targets of NFAT1, cDNA microarray was performed in A375SM
metastatic melanoma cell line after NFAT1 silencing. Among the genes that were
downregulated, MMP-3 (also known as stromalysin-1) was downregulated by more than 3
fold after NFAT1 silencing. In order to validate the cDNA results, A375SM and WM902B
metastatic melanoma cell lines, which express high levels of NFAT1, were stably transduced
with a NFAT1 lentiviral shRNA construct and western blot analysis was performed to
demonstrate the NFAT1 silencing. The results demonstrated that NFAT1 expression was
reduced by 75% in A375SM and in 58% in WM902B cells. Furthermore, SB2 cells that
express low NFAT1 levels, were transduced with an overexpression vector for NFAT1
(Figure 7). The MMP-3 gene was recognized as a downstream target of NFAT1 after a
cDNA array was performed on A375SM NFAT1 silenced cells. From the array data we can
see more than a 3 fold reduction in MMP-3 expression after NFAT1 silencing (Table 1). For
further validation, western blot analysis for MMP-3 was performed after silencing NFAT1 in
A375SM and WM903B as well as after overexpressing NFAT1 in SB2 cells. Since MMP-3
is a secreted protein, in addition to a whole cell lysate western blot, we also performed a
western blot for the medium of the cells. The western blots were done using protein from
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whole cell lysate and from concentrated medium after the cells were serum starved for 48hr.
The results of the western blot revealed a 50% decrease in A375SM and a 15% in WM902B.
When the protein was extracted from whole cell lysates, a 40% reduction in A375SM and
65% reduction in WM902B was observed when the protein was obtained from conditioned
media. After NFAT1 overexpression in SB2 cells, an increase of 48% in the expression of
MMP-3 was observed when protein extract was generated from conditional media and 33%
in whole cell lysate (Figure 16). The densitometry for the whole cell lysates was analyzed
compared to actin and for conditional media, it was compared to a media loading control.
Taken together, the secretion of MMP-3 is decreased after silencing NFAT1 and the opposite
results were observed in SB2 after NFAT1 overexpression. The secretion of MMP-3
increases after overexpressing NFAT1 in the low metastatic cell lines (Figure 16).
Furthermore, since MMP-3 is a secreted protein, an ELISA assay was performed (Figure 17).
In the ELISA assay we included A375SM and WM902B cell lines both after NFAT1
silencing and after rescue of NFAT1. The rescue of NFAT1 also rescued the expression of
MMP-3, demonstrating that the downregulation of MMP-3 after NFAT1 silencing is not an
off target effect but directly regulated by NFAT1. We also included the SB2 low metastatic
cells in which NFAT1 was overexpressed. The ELISA results showed a significant reduction
of MMP-3 secretion after NFAT1 silencing in both A375SM and WM902B. To further
validate that indeed the downregulation of MMP-3 is directly regulated by NFAT1 silencing
and not from off target effects, we rescued NFAT1 in both A375SM and WM902B cell lines
(Figure 11). After NFAT1 rescue there was a complete rescue of the MMP-3 secretion,
where the secretion levels returned back to NT levels in both cell lines. In SB2 cells we can
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see a significant increase in MMP-3 secretion levels after NFAT1 overexpression in both
western blot and the ELISA assays (Figure 16, Figure 17).
Rescue of MMP-3 in Melanoma Cells Results in the Rescue of NFAT1
Lentiviral based shRNA is a very powerful and useful tool for silencing target genes.
However, using this method may cause nonspecific effects. These effects are possible results
of antiviral response to the double stranded mRNA or can be due to targeting different genes.
To rule out these effects, and to make sure our shRNA construct is on target for NFAT1,
NFAT1 was rescued in both A375SM and WM902B melanoma cell lines. We were able to
rescue NAFT1 successfully in both cell lines as presented in figure 11. The NFAT1
overexpression resulted in re-expression of MMP-3 in both cell lines while the empty vector
(EV) control had no effect on these genes as demonstrated by qPCR in figure 12 and by the
ELISA assay presented in figure 17. Therefore, we concluded that the regulation of MMP-3
by NFAT1 is not generated due to an off target effect of the shRNA construct, but occurs
through NFAT1.
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Figure 16: Silencing NFAT1 Decreases MMP-3 Expression in Melanoma Cells. Western blot
using MMP-3 antibody to learn about protein levels. The results show approximately a 40-65%
reduction of MMP-3 expression within the supernatant in A375SM and WM902B respectively.
Coomassie blue staining of the membrane was used to confirm equal loading of the supernatant.
Overexpression of NFAT1 in low metastatic SB2 melanoma cells increases the expression of MMP-3
in the supernatant by approximately 50%.
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Figure 17: Rescue of NFAT1 Rescues the Protein Levels of Secreted MMP-3. ELISA assay for
the secreted protein MMP-3. Results demonstrate that after NFAT1 silencing, the levels of MMP-3
are downregulated and when we rescue the expression of NFAT1, the levels of MMP-3 are also
rescued in both A375SM and WM902B melanoma cell lines. SB2 overexpressing NFAT1 caused
upregulation of MMP-3 expression.
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NFAT1 Enhances the Promoter Activity of MMP-3
Our cDNA microarray results indicated that NFAT1 regulates MMP-3 in the mRNA level
(Table 1). However, we had yet to determine whether this is a transcriptional regulation. To
answer that question we performed qRT-PCR and as observed the expression of MMP-3
mRNA was decreased by ~5 fold in both NFAT1 silenced A375SM and by ~3 fold in
WM902B NFAT1 KD melanoma cells (Figure 12A,B), corroborating the cDNA microarray
results. For the SB2 low metastatic cell line in which NFAT1 was overexpressed, an increase
of ~7 fold was observed in MMP-3 expression (Figure12 C). These results demonstrate that
NFAT1 regulates MMP-3 in the transcriptional level. Since NFAT1 is a transcription factor
we reasoned that the reduced MMP-3 protein expression after silencing NFAT1 is due to less
binding of NFAT1 to the MMP-3 promoter.

To that end, we utilized chromatin

immunoprecipitation assay using an anti-NFAT1 antibody to pull down NFAT1-DNA
complexes in A375SM, WM902B and SB2 melanoma cells. End point PCR was performed
on the surrounding area of the first NFAT1 binding site on the MMP-3 promoter, which is
located at -414bp from the transcription initiation site. NFAT1 binds to the promoter of
MMP-3 in both A375SM and WM902B melanoma cells. When NFAT1 is silenced (NFAT1
KD), no binding to the MMP-3 promoter in both melanoma cell lines was observed (Figure
18A). In SB2 the binding was observed after overexpressing NFAT1 in the cells and was not
observed in the empty vector control cells (Figure 18A). The ChIP assay confirms that
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NFAT1 binds to the MMP-3 promoter and that binding is lost after NFAT1 silencing.
However, it was not yet clear if NFAT1 directly binds to the MMP-3 promoter, which
binding site is more significant and if that binding had an effect on transcriptional activation.
To further determine the regulation mechanism, the dual luciferase promoter assay was used.
MMP-3 promoter (-1500 to the TIS) was cloned in front of the luciferase reporter gene. The
luciferase activity driven by the MMP-3 promoter and was significantly decreased after
NFAT1 silencing, ~4 fold in A375SM and ~7 fold in WM902B (Figure 19 A,B). In NFAT1
overexpressing cells, the promoter activity of SB2 was significantly increased (~3 fold), after
NFAT1 overexpression (Figure 19 C). These results indicate that NFAT1 regulates MMP-3
at the transcriptional level. To further prove that NFAT1 directly binds to the MMP-3
promoter we generated luciferase constructs with mutations which were inserted into the
binding sites. Three constructs were made, the first has a mutation in the first binding site,
MMP3-mut1 (site 414), the second construct had a mutation in the second binding site
MMP3-mut2 (site 1291) and the third construct had mutations in both binding sites MMP3ded (‘ded’ stand for double edited, mutations in both sites). When the mutations were
inserted, there was a significant decrease in luciferase activity in the control samples
(A375SM NT, WM902B NT). Interestingly, both mutations had approximately the same
effect (no significant different was observed) on the promoter activity and the dual mutation
had no additive effect (Figure 19). These results suggest that both sites are equally important
for the transcription activation of MMP-3.
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Figure 18:

NFAT1 binds to the Promoter

Region of

MMP-3 (A) Chromatin

immunoprecipitation of NFAT1 on the MMP-3 promoter is lost when NFAT1 is silenced in A375SM
and WM902B cells, binding is increased when NFAT1 is overexpressed in SB2 cells (B) Two
NFAT1 binding sites are located on the mmp-3 promoter within the first 1500bp of the transcription
initiation site. First site is at -414bp, second site at -1291bp.
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Figure 19: Dual Luciferase MMP-3 Promoter Activity is Reduced in the Presence of NFAT1
Binding Site Mutations. Silencing NFAT1 in both A375SM and WM902B significantly reduced the
luciferase promoter activity of the wild type promoter by approximately 75% as compared to NT
shRNA. Mutating NFAT1 binding sites (each one separately or both) resulted in reduced promoter
activity compared to the wild type promoter; P < 0.05. (A) A375SM melanoma cells (B) WM902B
melanoma cells after silencing NFAT1 (C) SB2 melanoma cells after overexpressing NFAT1.
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Sub Aim 2.3: Determine the Contribution of MMP-3 to Melanoma Growth and
Metastasis

Results
MMP-3 Expression is Positively Correlated in Melanoma cell lines
Although we already identified that MMP-3 mRNA and protein levels are reduced after the
silencing of NFAT1, we have yet to determine whether the expression levels of MMP-3 has
any relevance in melanoma growth and metastasis. To our knowledge, the correlation
between MMP-3 and metastatic potential was not yet established for melanoma. To study
whether MMP-3 expression is correlated with the metastatic potential of the cell lines we
used ELISA assay to measure MMP-3 secretion from a panel of cell lines. The cells that
were used in this panel are the same cells that we used in the NFAT1 panel: SB2, DM4,
Mewo, TXM18, A375SM, WM2664 and WM902B.

The results from the ELISA

demonstrated a direct correlation between the metastatic potential of the cell lines and MMP3 secretion.
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Figure 20: Positive Correlation between the Metastatic Potential of Melanoma Cell Line to
MMP-3 protein Expression. ELISA assay for a panel of melanoma cell lines used in our lab . The
less tumorigenic SB2, and DM4 melanoma cell lines they secreted significantly less MMP-3 than the
more tumorigenic and metastatic Mewo, TXM-18, A375SM, WM2664 and WM902B cells. These
results correlate with the western blot analysis for NFAT1 expression in the same panel of cells that is
presented in Figure 4.
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The Overexpression of MMP-3 Rescues Tumor Growth and Metastasis In Vivo
To study the role of MMP-3 in melanoma growth and metastasis, we decided to overexpress
MMP-3 in the SB2 low metastatic cell line, which expressed low levels of MMP-3, and
silence MMP-3 expression in A375SM, a highly metastatic cell line with high expression of
MMP-3. We generated a stable SB2 cell line with high levels of MMP-3, and stable A375SM
cell lines with silenced MMP-3. The expression of the MMP-3 was validated using ELISA
assay, as presented in figure 21. These cells (A375SM NFAT1 shRNA, SB2 NFAT1
overexpression) were then injected both subcutaneously and intravenously into nude mice to
investigate tumor growth and experimental lung metastasis assays respectively. As control
groups A375SM NT and SB2 EV cells were injected. Tumor volume was measured for 28
days for the following injected groups; A375SM NFAT1 shRNA vs. A375SM NT and SB2
NFAT1 OE vs. SB2 EV. As seen in figure 22, our in vivo studies demonstrate that MMP-3 is
an important player in melanoma tumoregenicity. Indeed, 3 weeks from injections, there was
a significant difference in the tumor size. In A375SM the control group (A375SM NT)
presented a higher tumor volume than A375SM MMP-3 shRNA. At day 28 the tumor size of
the control group reached a mean of 1100mm3 while the tumor size, after silencing MMP-3,
had a mean of only 450mm3 (Figure 22A). Accordingly we found that overexpression of
MMP-3 in SB2 cells increased their tumor growth. The MMP-3 overexpression group
presented a mean of 700mm3 at day 28 compared to a mean of 200mm3 in the empty vector
group (Figure 22B). The results for the experimental lung metastasis also supported the
hypothesis that high levels of MMP-3 contribute to a higher number of experimental lung
metastases. We found that the mean number of lung metastases derived from A375SM NT
was significantly higher when compared to the A375SM MMP-3 shRNA group (mean of 56
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compared to 25 respectively). The differences in the number of lung metastases were also
significant in the SB2 group. The number of lung metastasis after overexpressing MMP-3
was higher than the empty vector control group (mean of 9 compared to 4). Taken together,
we conclude that MMP-3 expression is a contributor for the malignant phenotype of
melanoma cell lines.
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Figure 21: MMP-3 ELISA Demonstrating a Verification of MMP-3 Silencing in A375SM and
MMP-3 Overexpression in SB2 Cells. ELISA assay for the secreted protein MMP-3. Results
demonstrate a successful silencing of the protein levels of MMP-3 with both targets (KD1,KD2).
Results also demonstrate a significant overexpression of MMP-3 in SB2 cells (*P<0.05).

92

Figure 22: MMP-3 Expression is Required for Melanoma Tumor Growth and Metastasis In
Vivo
Silencing MMP-3 in A375SM melanoma cells reduces tumor growth and experimental lung
metastasis in nude mice while overexpression of MMP-3 in SB2 increases both tumor growth and
metastasis. (A) A375SM melanoma cells were injected subcutaneously in nude mice and tumor
growth was monitored for 28 days. Tumor growth was significantly reduced after silencing MMP-3
at day 28, tumor volume mean of 1100mm3 compared to 450mm3 (*P < 0.05). (B) SB2 melanoma
cells were injected subcutaneously into nude mice and monitored for 28 days. Tumor growth was
significantly increased after overexpressing MMP-3; mean tumor volume of 200 mm3 compared to
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700 mm3 (*P<0.05) (C) Six weeks after intravenous injections of A375SM cells, nude mice were
sacrificed and the number of lung metastasis were counted. Silencing MMP-3 significantly reduced
the number of experimental lung metastasis; mean of 56mets compared to 25 mets (P* < 0.05). (D)
Six weeks after intravenous injections of SB2 cells, nude mice were sacrificed and the number of lung
metastasis was counted. Overexpressing MMP-3 significantly increased the number of experimental
lung metastasis; mean of 4 mets compared to 9 mets (P* < 0.01).
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Immunohistochemistry for the Expression of Downstream Targets In Vivo
We next investigated the expression of IL-8, MMP-3 and CD31 at the tumor level using
immunohistochemistry of the tumor sections from the in vivo study (presented in Figure 10).
The staining confirmed that indeed IL-8 and MMP-3 expression are decreased in vivo in
A375SM cells in which NFAT1 was silenced and MMP-3 and IL-8 expression were
increased after overexpressing NFAT1 in SB2 cells (Figure 23).
To verify the angiogeneic role of IL-8, further immunohistochemistry staining was
performed on both A375SM and SB2 xenograft tumors with anti-CD31, a widely used
endothelial marker, detecting blood vessels (angiogenesis). A375SM, NFAT1 NT shRNA
melanoma cells present a high number of blood vessels when compared to NFAT1 shRNA.
The overexpression of NFAT1 in SB2 cells shows similar phenotype as the highly metastatic
line A375SM, and it is clearly noticeable that the number of blood vessels is higher after
NFAT1 overexpression compared to the empty vector SB2-EV (Figure 23). Apoptosis was
also analyzed in the tumor sections from our xenograft model using the TUNEL assay. The
number of positively stained (dead) tumor cells was significantly increased in NFAT1
silenced A375SM tumors. The overexpression of NFAT1 in SB2 cells reduced the number
of apoptotic cells (Figure 23).
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TCGA Analysis for the Expression of IL-8 and MMP-3 and Survival
To further validate the relevance of our downstream target genes in the clinics, we mined the
TCGA data to investigate if there is a correlation between the expression levels of IL-8 and
MMP-3 to the survival of patients. The analysis was based on 45 patients that expressed IL-8
or MMP-3. The results demonstrated that patients with higher expressions of these genes had
a significantly worst overall survival (p<0.05) than patients with low expression of these
proteins (Figure 24).
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Figure 23: Immunohistochemistry of Tumor Samples after Silencing or Overexpressing NFAT1
in Melanoma Cells
A375SM melanoma cells with NT /NFAT1 shRNA and SB2 cells with Empty vector/NFAT1 OE
were injected subcutaneously in nude mice. NFAT1 remains silenced or Overexpressed in the
xenograft tumors (upper panel). NFAT1 downstream targets are demonstrating up- and downregulation as expected (second and third panel). A representative image of the number of CD31
positive endothelial cells is shown from A375SM and SB2 xenograft tumors (fifth panel). Silencing
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NFAT1 reduces the number of CD31 stained blood vessels within the tumor, while overexpression of
NFAT1 increases the number of blood vessels. Silencing of NFAT1 increases the number of
apoptotic TUNEL positive cells within the subcutaneous tumor. Overexpression of NFAT1 in SB2
cells reduces the number of apoptotic cells in the xenograft model.
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A.

B.

Figure 24: Expression of IL-8 and MMP-3 Correlates with Survival in Patients (based on 45
patients from TCGA data)
Analysis based on TCGA data demonstrating a correlation between survival of patients to levels of
the proteins IL-8 and MMP-3 in their tumors. (A) Patients with higher IL-8 expression showed a
lower overall survival (in red) compared with patients have low IL-8 expression (in blue) (B) Patients
with higher MMP-3 expression showed a lower overall survival (in red) compared with patients that
have low MMP-3 expression (in blue)
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Summary Specific Aim 2
In this aim we identified two novel downstream target genes that are regulated by
NFAT1 and contribute to melanoma progression. We established that there is a positive
correlation between NFAT1 expression with IL-8 and MMP-3 protein expression. We first
demonstrated that IL-8 is positively regulated at both the transcriptional level and protein
levels by NFAT1. Silencing of NFAT1 in A375SM and WM902B metastatic cell lines
resulted in downregulation of IL-8 mRNA and secreted protein levels. Rescue of NFAT1 in
those two cell lines also rescued the IL-8 expression at both mRNA and protein levels, which
emphasizes that IL-8 is directly regulated by NFAT1 expression and not due to an off target
effect of the transduction. Moreover, when overexpressing NFAT1 in the low metastatic cell
line SB2, IL-8 mRNA and secreted protein levels were increased. Furthermore, we
demonstrated that NFAT1 enhances the promoter activity of IL-8 by utilizing ChIP assay.
Mutation on the NFAT1 binding site on IL-8 promoter resulted in a significant reduction in
luciferase activity, indicating a direct binding of NFAT1 to the IL-8 promoter. At last we
demonstrated using immunohistochemistry staining, that the regulation of IL-8 and MMP-3
is also maintained in vivo in the tumor tissue from the xenograft model.
The second novel target that is regulated by NFAT1 is MMP-3. Little is known about
the contribution of MMP-3 in melanoma. A possible role of MMP-3 in the progression and
metastasis was previously suggested as MMP-3 protein levels were reported to be expressed
in highly metastatic melanoma cell lines [155, 156], however the role of MMP-3 in
melanoma progression was not elucidated. In our study, we validated that indeed the cell
lines that are used in our lab also have a similar expression profile when looking at MMP-3.
The more metastatic the cell line is, the higher the MMP-3 expression level it has. In this
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study we found that silencing NFAT1 in A375SM and WM902B metastatic melanoma cell
lines reduced MMP-3 mRNA and protein expression levels. In SB2 cells, overexpression of
NFAT1 increased the expression of MMP-3 at both the transcriptional and protein levels. We
further demonstrated that NFAT1 enhances the activity of the MMP-3 promoter. MMP-3
promoter has two NFAT1 binding sites and mutation analysis of the promoter showed that
both binding sites has the same effect on the promoter activity (no significant difference was
observed) and dual mutation had no additive effect. Silencing NFAT1 or mutation in the
binding site reduced the luciferase activity of the MMP-3 promoter further establishing the
role of NFAT1 in the transcriptional regulation of MMP-3. Finally we aimed to elucidate the
role of MMP-3 in melanoma tumor growth and experimental metastasis. We silenced MMP3 expression in a metastatic melanoma cell line (A375SM) and overexpressed MMP-3 in a
low metastatic cell line (SB2). These cell lines were then utilized for in-vivo studies, where
they were injected subcutaneously and intravenously to investigate the effect of MMP-3 on
melanoma tumor growth and metastasis. Our results demonstrate that higher expression of
MMP-3 in the cells promoted tumor growth and metastasis, which emphasizes the
importance of MMP-3 to the metastatic phenotype.
To validate the clinical relevance of our results, we mine the TCGA data and found a
correlation between the expression levels of IL-8 and MMP-3 to the overall survival of
patients. Patients with lower levels of IL-8 and MMP-3 show a significantly better survival
than patients with high expression of the proteins.
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CHAPTER 5: Discussion, Significance and Future Directions

The role of NFAT1 in the immune response as a T cell activator is very well established. Its
role in cancer and more so in melanoma is less documented. During this study we revealed
several novel findings, which further elucidate the role of NFAT1 in melanoma progression.
We demonstrated that NFAT1 expression positively correlated with the metastatic melanoma
phenotype in both patient specimens as well as in a panel of cell lines with different
metastatic potential. In patient specimens, we demonstrated that NFAT1 expression is
significantly higher in metastatic lesions compared to patients with primary tumors. In cell
lines, NFAT1 expression increased with the metastatic potential of the cells. To further
establish the contribution of NFAT1 in melanoma metastasis, we silenced NFAT1 expression
by lentiviral shRNA in two metastatic melanoma cell lines A375SM and WM902B. We
found that silencing NFAT1in both cell lines significantly reduced their invasive potential in
vitro. Overexpression of NFAT1 in the low metastatic melanoma cell line, SB2 significantly
increased their invasive potential in vitro. In vivo, we demonstrated that silencing of NFAT1
reduced the tumor growth and metastatic potential of A375SM melanoma cells while
overexpression of NFAT1 in the low metastatic SB2 cells increased their in vivo metastatic
properties. To further elucidate the mechanism of action of NFAT1 in melanoma progression
we subjected the metastatic melanoma cell line A375SM NFAT1-silenced cells to a cDNA
microarray analysis. We found that NFAT1 positively regulates the expression of IL-8 and
MMP-3 at the transcriptional level. Chromatin immunoprecipitation assays as well as
promoter analysis demonstrated that NFAT1 binds to the promoter of IL-8 and MMP-3 and
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promotes their transcription. Rescue of NFAT1 expression in NFAT1-silenced cells restored
the protein expression of both IL-8 and MMP-3. This confirms that our results are not an
off-target effect of the sh-NFAT1 used in our studies.
The role of IL-8 in melanoma progression and metastasis has been previously established in
our laboratory. We therefore decided to concentrate our further studies on elucidating the role
of MMP-3 in promoting the metastatic melanoma phenotype. In cell lines we demonstrated
that secreted MMP-3 levels increased with the metastatic potential of the cells. To further
elucidate the role of MMP-3 in melanoma progression, we stably silenced MMP-3
expression using letiviral shRNA in the highly metastatic A375SM cells and overexpressed
MMP-3 in the low metastatic SB2 cells. These cells were injected into nude mice, both
subcutaneously and intravenously, to study the role of MMP-3 in tumor growth and
metastasis. In vivo, we demonstrated that silencing of MMP-3 reduced tumor growth and the
metastatic potential of A375SM melanoma cells, while overexpression of MMP-3 in the low
metastatic SB2 significantly increased their tumor growth and metastatic potential. Mining
the TCGA data, we demonstrated that patients with low expression of IL-8 or MMP-3 have
significantly better survival rate when compared to patients with high expression of these
proteins.
Taken together my work assigns a previously undescribed role for NFAT1 in regulating the
melanoma metastatic phenotype.
The main cause of mortality in the majority of melanoma patients is due to distal
metastases. Regardless of the latest advances in the field, such as BRAF and
immunocheckpoint modalities, malignant melanoma still presents a major clinical challenge.
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During melanoma progression, there is a signature of genetic alterations, but to better
promote the field it is critical to understand the regulation and mechanisms associated with
metastasis. Therefore, recognizing the events, and genes involved that lead to melanoma
metastasis is essential for identifying novel therapeutic molecular targets that will
successfully cure this disease.
Earlier reports have described the correlation between NFAT1 and melanoma. One
such published work had demonstrated that the absence of NFAT1 expression in the
microenvironment caused a significant difference in the ability of the B16F10 melanoma cell
line to grow [116]. NFAT1 deficient mice presented less experimental lung metastasis
colonization after B16F10 melanoma cell injections when compared to the WT mice [116].
Another related publication presentd NFAT1 as a potential therapeutic target in melanoma,
since NFAT1 was found to promote proliferation and inhibits melanoma cell apoptosis [117].
In addition, NFAT1 was found to be an activating transcription factor for the MDM2
oncogene in response to DNA damage signals [118]. NFAT1 also supports tumor induced
anergy of CD4+ T cells [119] and regulates a set of genes that are responsible for helper Tcell (CD8+) anergy [120]. Data from a recent publication has demonstrated that NFAT1
increased CTLA-4 promoter activity in CD4+ T cells compared to CD8+ T cells. The
expression of CTLA-4 mediated by NFAT1 in CD4+ can potentially be important for anti
CTLA-4 therapy [121]. Our laboratory has previously demonstrated that Gal-3 regulates
autotaxin through NFAT1, and high levels of Gal-3 supports melanoma growth and
metastasis [122]. Taken together, these data indicate that NFAT1 regulates multiple genes
during melanoma progression. However, the majority of the downstream genes have yet to
be identified. The present study showed that indeed NFAT1 positively correlates with the
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metastatic potential of melanoma cell lines although the mechanism by which NFAT1
contributes to melanoma progression remains unknown. In the effort to identify downstream
target genes regulated by NFAT1, NFAT1 shRNA was used to silence NFAT1 in A375SM
cells and a CDNA microarray was performed. We narrowed our study on two downstream
target genes: IL-8 and MMP-3. NFAT1 was also overexpressed in the low metastatic cell line
SB2 and both manipulated cell lines (A375SM and SB2) were injected into nude mice both
subcutaneously (for tumor growth) and intravenously (for experimental lung metastasis) to
clarify the role of NFAT1 in tumor growth and metastasis. Results from the in vivo
experiment revealed that overexpressing NFAT1 in the low metastatic cells increased tumor
growth and metastasis while silencing NFAT1 significantly reduced tumor growth and
metastasis. Our data validate the assertion that NFAT1 has an active role in melanoma
progression and metastasis formation. Moreover, upon mining available TCGA data we
found that NFAT1 is expressed more in metastatic lesions compared to specimens taken from
benign nevi (Figure 5) so it is consequently clinically relevant to consider NFAT1 and its
downstream regulated genes, IL-8 and MMP-3, as possible targets to melanoma therapy.
Imunohistochemistry performed on tumors from the in vivo study demonstrated that in the
absence of NFAT1, less blood vessels formation and increased apoptosis were observed.
Imunohistochemistry staining also demonstrated that the correlation between NFAT1 and its
downstream genes is conserved in vivo. Silencing NFAT1 reduced IL-8 and MMP-3
expression in the tumor tissue suggesting that its role in regulating crucial downstream
targets which are necessary for dimelanoma progression. Thus, the NFAT1 transcription
factor may be an important factor to promote melanoma progression.
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The chemokine IL-8 is one of the downstream targets identified as being regulated by
NFAT1 and its expression is shown to be positively correlated with melanoma progression
[134-136]. Overexpression of IL-8 in melanoma cells up-regulates the expression and
activity of the matrix metalloproteinase MMP-2, which contributes to a more invasive
phenotype [137]. Targeting IL-8 could be therapeutically beneficial for melanoma patients,
due to the pro-tumorigenic and survival dependent effects of IL-8 in cancer. Using a fully
human antibody against IL-8 (ABX-1L8) we demonstrated its effect on melanoma growth
and metastasis. ABX-IL8 significantly reduced tumor growth and experimental lung
metastasis of A375SM and TXM-13 melanoma cells in vivo mostly by inhibiting
angiogenesis [141]. IL-8 has been shown to promote the growth, invasiveness, motility,
angiogenesis, and metastatic potential of melanoma cells [137, 141-143]. Interestingly,
targeting IL-8 reduced MMP-2 expression, and incubating melanoma cells with ABX-IL-8
reduced the invasive potential of melanoma cells through Matrigel coated membranes.
Decreased CD31 staining in vivo and HUVEC tube formation in vitro was also observed
[141]. In a new ongoing study in the lab, a siRNA delivery approach is being utilized to
silence IL-8 to reduce melanoma growth and metastasis in vivo.
The second downstream target, MMP-3, is less investigated in melanoma. MMP-3
was investigated as a potential serum marker and the levels of MMP-3 in the serum were
evaluated between healthy patients and malignant melanoma patients but no significant
differences observed [146, 147]. Another in vivo study reported that Angpt2, MMP-3 and
MMP-10 are all upregulated in the lung by a mice bearing the B16F10 tumors [151]. The
lung microenvironment is therefore presenting the pre-metastatic niche that resulted through
the influence of the primary tumor. Recently, SOX2 (an embryonic stem cell transcription
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factor) was found to be expressed in human melanoma cells [152, 153]. It was also shown
that after silencing SOX2 in melanoma cells, the expression of MMP-3 was reduced by
almost 90% [154]. From the association between SOX2 and MMP-3, it was suggested that
MMP-3 is regulated by SOX2 and that their co-expression may be used as a functional
biomarker for invasive melanoma cells [154].

Data from our current study showed that

NFAT1 binds to the MMP-3 promoter and regulates its expression. Also, we validated that
there is a direct correlation between MMP-3 protein levels with the metastatic potential of
melanoma cell lines. To further clarify the role of MMP-3 in melanoma progression we
utilized A375SM cells with MMP-3 shRNA and SB2 cells with MMP-3 overexpression.
Both manipulated cell lines were injected subcutaneously and intravenously to study the role
of MMP-3 in tumor growth and metastasis. In SB2 cells, higher MMP-3 expression resulted
in an increase of tumor growth and experimental lung metastasis. In contrast, silenced
MMP-3 in A375SM cells resulted with a significant reduction in both the number of
metastases and tumor size (Figure 22).

Evidence from this investigation led to the

conclusion that NFAT1 is a regulator of a number of important genes that support melanoma
growth and metastasis including IL-8 and MMP-3. Hence, NFAT1 expression is essential
for melanoma progression. Our findings identify a previously unknown mechanism by
which NFAT1 promotes melanoma growth and metastasis through its positive regulation of
IL-8 and MMP-3 protein expression.
Therapies for the treatment of metastatic melanoma that target NFAT1, IL-8 or
MMP-3 have not yet to been studied. Throughout our study, we identify a novel mechanism
for melanoma progression in which NFAT1 regulates IL-8 and MMP-3 and promotes the
malignant phenotype. Targeting NFAT1 could be a potential therapeutic tool. Therapy
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directed at NFAT1 is clinically feasible as shown with cyclosporine A to inhibit T-cell
mediated organ transplant rejection [157]. However, in melanoma, immunotherapy and
immunesurveillance promoted by T-cells are considered methods for melanoma treatment.
Therefore, systemic therapy directed towards NFAT1 in melanoma could be counterintuitive
by reducing T-cell activity. Yet, not all T-cells have anti-tumor function. Regulatory T-cells
(Treg) can reduce the immune response towards tumors, and it’s been shown that NFAT1
enhances Treg activity as well (Reviewed in [158, 159]). The multiple roles of NFAT1
within the tumor microenvironment create a “double edged sword” in regards to its
therapeutic potential. Therefore, directing therapy towards the downstream targets IL-8 and
MMP-3 instead of NFAT1 could be a better choice.

The impact of these findings can translate to the clinic by improving treatment
options for metastatic melanoma. Results suggest that targeting IL-8, MMP-3, or both as
therapy for melanoma is possible either alone or in combination with immunotherapy or
chemotherapy. Data from the survival curves (Kaplan Meier) reveal a potential connection
between IL-8 and MMP-3 expression and patient survival highlighting the likely success of
utilizing these two targets for therapeutic purposes. Treatment options focused on targeting
IL-8 and MMP-3 can be taken towards several directions including finding the connection
between IL-8 expression and BRAF resistance in melanoma cells. Further analysis may
examine the change in IL-8 levels due to resistance and whether the use of IL-8 inhibiting
antibody will regress cellular resistance to BRAF inhibitors.

Based on our results, it can be established that after silencing NFAT1, reduction in
tumor size can be partially due to a reduction in angiogenesis resulted from a decrease in IL108

8 expression. These data suggest that NFAT1 may promote melanoma by functioning as a
regulator of downstream targets that in turn can be affecting interactions with the
microenvironment.

Our previous data present a novel mechanism in which autotaxin is regulated by Gal3 through NFAT1 [122]. Along with our current data, this implicates that NFAT1 plays
major roles in modulating the tumor microenvironment to support melanoma growth and
metastasis (Figure 25). Taken together, our findings establish a novel mechanism by which
NFAT1 contributes to melanoma growth and metastasis through the regulation of IL-8 and
MMP-3. This is the first report of a mechanistic role of NFAT1 in melanoma progression and
serves as foundation for future studies in this area.
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Figure 25: Proposed Mechanism for the Role of NFAT1 in Melanoma Progression
Increased of NFAT1 expression in metastatic melanoma cells promotes its activation as a
transcription factor in the nucleus. Therefore, promotes its downstream target genes. IL-8 and MMP-3
are supporting angiogenesis, invasion and cell survival, and result increase in tumor growth and
metastasis.
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